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Protein kinases, many of which are regulated by autophosphorylation, modify their 
substrates by phosphorylation.  Due to their roles in cellular signaling cascades controlling 
processes such as cellular proliferation, differentiation, metabolism, and apoptosis, protein 
kinases have caught the attention of scientists.  In this study, we characterized the 
regulation and functions of two human membrane-bound protein kinases, TRPM7 and 
PERK.  
TRPM7 (transient receptor potential melastatin 7) is a non-selective cation channel 
fused to an atypical kinase domain at the C-terminus that is implicated in cellular 
magnesium homeostasis.  While the channel properties of TRPM7 have been studied 
extensively, little is known about the mechanisms regulating its kinase activity. 
Furthermore, to date, no specific small molecule inhibitor of TRPM7 kinase has been 
identified.  Therefore, we characterized the biochemical and functional properties of 
TRPM7 autoactivity and discovered the first group of small molecule compounds targeting 
the kinase activity.  Through a broad range of biochemical assays, we demonstrated that 
early autophosphorylation on three serine residues is required for TRPM7 kinase activity.  
vii 
These phosphorylations promote a tetramer to dimer transition of the catalytic domain, as 
well as its cellular association with myosin.  Aided by the discovery of effective kinase 
inhibitors a role for the kinase domain in actomyosin contractility and migration was 
examined. 
PERK (PKR-like endoplasmic reticulum kinase) is a serine/threonine kinase, 
resident in the ER membrane and activated by the unfolded protein response (UPR), which 
detects the accumulation of unfolded proteins in the ER.  The UPR and PERK are up-
regulated in a variety of tumor types and may be critical for cancer cell adaptation.  
Therefore, a goal of this study was to identify PERK inhibitors that will provide new 
potential therapeutic strategies for treating cancer.  We discovered a number of lead 
compounds and validated their ability to inhibit PERK kinase activity in vitro.  The most 
potent PERK inhibitor was further tested to evaluate the modulation of the PERK signaling 
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Chapter 1: Introduction 
 
1.1 FUNCTIONS AND REGULATION OF TRPM7 CHANNEL 
Transient receptor potential (TRP) cation channels constitute a large protein 
superfamily.  Physiologically, TRP channels function as cellular sensors responding to 
various stimuli such as temperature, taste, pain, sound and mechanical stress (1-4).  All TRP 
members contain six transmembrane segments with the pore loop positioned between the 
fifth and sixth transmembrane domains, which together form the cation-permeable pore (3).  
The transient receptor potential melastatin (TRPM) family has eight members representing 
a wide range of structural features, expression patterns, ion selectivity and gating properties 
and functions.  The TRPM family is divided into four groups based on mammalian 
sequence homology: TRPM1/3, TRPM6/7, TRPM2/8, and TRPM4/5 (3, 5).  TRPM7 
consists of 1863 amino acids and was cloned by two groups (6, 7).  It is ubiquitously 
expressed, but with highest mRNA expression levels detected in the brain, heart and kidney 
(6, 8, 9).  Like most TRP channels, TRPM7 channels have six transmembrane domains, with 
a pore-forming domain between the fifth and sixth transmembrane domains.  TRPM7 
encodes a divalent cation channel fused to an atypical kinase domain at the C-terminus 
(figure 1.1) (10).  This kinase is a member of a small family of kinases that include 
elongation factor 2 (eEF2) kinase, and myosin heavy chain kinase A from Dictyostelium 
discoideum (7).  How the atypical kinase domain regulates the channel function of TRPM7 
remains unclear.   
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TRPM7 is a non-selective cation channel, which is permeable to divalent cations 
such as Mg2+ and Ca2+, as well as other trace metals including Zn2+, Mn2+ and Ni2+ (8, 11, 12).  
Initial studies report that TRPM7 current (flux of ions) is inhibited by the binding of Mg2+ 
(near the pore) and Mg-ATP (in the kinase domain) (13, 14).  Its current is also inhibited by 
extracellular Zn2+and Gd3+ (15, 16).  In the absence of extracellular divalent cations, TRPM7 
has also been reported to conduct monovalent cations such as Na+ and K+, including 
protons (17).  In addition, TRPM7 is known to be regulated by the Src-family kinases, and 
PIP2 levels have been shown by other groups to be crucial for TRPM7 channel activation 
(18).  It remains controversial whether the receptor-mediated activation of phospholipase C 
(PLC), promoting hydrolysis of PIP2, leads to activation or inactivation of the TRPM7 
channel (19, 20).  Other research has also shown that TRPM7 currents are activated following 
a decrease in extracellular pH from physiological pH (7.4) to pH 4.0 (3, 17).   
TRPM channels have diverse C-terminal domains but share a common C-terminal 
cytoplasmic TRP domain and a coiled-coil domain.  Two TRP boxes located within the 
TRP domain possess significant sequence homology among the members of TRPC, 
TRPM, and TRPN subfamilies (3).  The coiled-coil domain is a widespread protein-protein 
interaction structural motif that is found in a variety of protein classes including motor 
proteins, fibrous proteins and membrane fusion proteins.  By use of size-exclusion 
chromatography, Tsuruda et al. demonstrated that a recombinant TRPM8 truncation 
protein containing the last 50 residues of the C-terminal cytoplasmic domain, forms a 
coiled-coil that is able to self-assemble into tetramers (21).  Furthermore, they demonstrated 
that this domain is required for the expression of functional channels at the plasma 
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membrane.  Recently, Fujiwara et al. resolved a high resolution crystal structure of the 
coiled-coil domain of TRPM7, which revealed that its overall structure is a tightly twisted, 
symmetric, and antiparallel tetramer (figure 1.2A) (22).   
Genetic and electrophysiological studies identified a major role of TRPM7 in the 
regulation of intracellular Mg2+ concentration, by showing that RNA interference or 
deletion of TRPM7 results in a decrease in intracellular Mg2+, cell cycle arrest and 
eventually cell death (8, 23, 24).  Recent studies showed that homozygous deletion of the 
TRPM7 kinase domain caused embryonic lethality while heterozygous mice displayed 
abnormal absorption of Mg2+ suggesting that TRPM7 is a key regulator of Mg2+ 
homeostasis (24).  Inhibition of TRPM7 channel activity can be achieved by increasing Mg2+ 
concentration and intracellular Mg-ATP levels.  Additionally, recent evidence suggests that 
TRPM7 activity contributes to various physiological functions in the cell, such as cell 
proliferation, neuronal cell death, neurotransmitter release, small synaptic-like vesicle 
fusion, and the regulation of actomyosin contractility (25-29).   
 
1.2 CHARACTERIZATION OF TRPM7 ALPHA-KINASE DOMAIN 
TRPM7 contains an atypical functional kinase domain which has specificity for 
serine and threonine residues (7, 30).  While the function and regulation of the TRPM7 
channel has been extensively studied, little is known about the molecular mechanisms that 
regulate the activity of the TRPM7 alpha-kinase domain and the role of the kinase domain 
in regulating the channel function remains controversial.  Runnels et al. reported that 
kinase-dead and Zn2+-binding mutants abolished channel activity measured in whole-cell 
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recording experiments, which suggest that the kinase activity is essential for TRPM7 
channel function (6).  Another group showed that mutation and deletion of the kinase 
domain of TRPM7 formed functional channels implying that TRPM7's kinase domain is 
not essential for activation of its channel (14).  Later, using whole-cell patch clamp analysis, 
Matsushita et al. argued that TRPM7 channel activity is functionally dissociated from its 
kinase activity, by showing that TRPM7 mutants that were mutated at two major 
autophosphorylation sites did not alter channel activity or regulation by internal Mg2+ (31).   
The TRPM7 alpha-kinase assembles into a dimer through the exchange of a 27-
residue-long N-terminal sequence that extends from residue 1551 to residue 1577 (figure 
1.2B) (32).  By analysis of truncation and site-directed mutants, Crawley et al. further 
divided the N-terminal segment into two parts; an ‘activation sequence’, encompassing 
residues 1553–1562, that is critical for kinase activity, but not dimer formation, and a 
‘dimerization sequence’, encompassing residues 1563–1570, that is required for both dimer 
formation and TRPM7 kinase activity (33).  These findings suggest that TRPM7 alpha-
kinase dimer formation plays a pivotal role in regulating enzyme activity.   
Like conventional protein kinases, TRPM7 undergoes autophosphorylation, but the 
functional consequences for kinase activity are not well understood.  Clark et al. identified 
autophosphorylated residues in TRPM7 by mass spectrometry and demonstrated that the 
cytosolic Ser/Thr-rich domain of TRPM7 is heavily autophosphorylated (32±4 mol/mol) 
(34).  Recent research has revealed that all three non-muscle isoforms of the myosin II heavy 
chain (IIA, IIB and IIC) are substrates of TRPM7 kinase (35, 36).  Myosin II interacts with 
actin and forms bipolar filaments, which are important for regulating actomyosin 
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contractility (12, 35-37).  The report that myosin II heavy chain is a downstream substrate of 
TRPM7 kinase suggests a potential role of TRMP7 in the regulation of the actomyosin 
cytoskeleton, in a manner which is analogous to the function of myosin II heavy chain 
kinase (MHCK A) in Dictyostelium.  In vitro biochemical assays were used to show that 
TRPM7 WT, but not the kinase-dead mutant (TRPM7-D1775A), phosphorylates and 
associates with myosin IIA in a regulated manner (36).  In addition, deletion of the 
autophosphorylation sites in the Ser/Thr-rich region of TRPM7 completely disrupted the 
phosphorylation of myosin II heavy chain, suggesting that TRPM7 interacts with the 
actomyosin cytoskeleton in a kinase-dependent manner to regulate myosin II activity and 
accordingly actomyosin contractility.  TRPM7 is also involved in regulating cytoskeletal 
dynamics by its association with annexin I (36, 38).  Once again, these findings indicate a 
potential role of the TRPM7 alpha-kinase domain in the regulation of cell adhesion and 
motility.   
 
1.3 CELLULAR FUNCTIONS AND ROLES OF TRPM7 IN CANCER 
As mentioned earlier, TRPM7 has been suggested to play a critical role in cell 
growth, proliferation and cell death.  The expression of TRPM7 is prevalent in the brain, 
spleen, lung, kidney, heart, liver and microglia.  TRPM7 overexpression was also found in 
cancer cells such as retinoblastoma, neck and head cells, gastric and breast cancer cells (23, 
39-44).  However, whether TRPM7 activity contributes to cancer progression has not been 
established.  Ca2+ and Mg2+ drive several cellular processes, and hence ion channels play a 
crucial role in the normal physiologic functioning of the cell.  However, dysregulation of 
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channel function has been implicated in promoting a variety of human diseases, including 
cancer.   
As a regulator of cell survival and death, TRPM7 is suggested to be a potential 
target for the pharmacological treatment of cancer.  Research in human gastric cancer cells 
has shown that blockade of TRPM7 channels or knockdown of TRPM7 expression by 
siRNA inhibited cancer cell growth and induced the apoptosis of these cancer cells (40).  
This implies the potential function of TRPM7 in the growth and proliferation of cancer 
cells.  Similarly, pharmacologic inhibition of TRPM7 channels by Gd3+, a nonspecific 
TRPM7 channel inhibitor, or knockdown of TRPM7 mRNA, suppressed the growth and 
proliferation of malignant head and neck tumor cells (39).   
Tumor metastasis is a hallmark of cancer and is defined as the ability of tumor cells 
to change their capacity to migrate, and permits them to adhere to other cells and tissues 
distant from the original tumor site (45, 46).  As TRPM7 is known to be implicated in 
modulating cell adhesion and migration through regulating cytoskeletal dynamics, 
researchers including Middelbeek and Guilbert, investigated whether TRPM7 is a key 
player in cancer cell metastasis (43, 44, 47).  Examination of the TRPM7 mRNA expression 
in the Oncomine database revealed that TRPM7 is closely linked with metastasis and 
invasive breast cancer (48).  Suppression of TRPM7 expression with RNA interference 
resulted in a significant decrease in the ability of breast cancer cells to migrate.  Moreover, 
a recent study from Guilbert et al. suggested that TRPM7 is involved in estrogen receptor-
negative metastatic breast cancer cell migration through its kinase domain.  They reported 
that overexpression of the truncation mutant lacking the kinase domain decreased cell 
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migration, while the overexpression of the WT TRPM7 significantly increased migration 
of the weakly metastatic MCF-7 and highly metastatic MDA-MB-231 cells by 2.5 fold (43).  
However, the molecular mechanisms underlying the contribution of TRPM7 to cancer cell 
proliferation and migration is still far from being understood.  Taken together, these 
findings increase the possibility that TRPM7 could be a new and potential therapeutic 
target for the treatment of cancer.   
 
1.4 THE UNFOLDED PROTEIN RESPONSE (UPR) SIGNALING  
The endoplasmic reticulum (ER) is an organelle that has essential roles required for 
normal cellular functions, including calcium homeostasis, protein secretion and lipid 
biosynthesis.  In eukaryotic cells, the ER provides a unique environment for the proper 
folding and posttranslational modification of several secretory and transmembrane proteins 
(49, 50).  Approximately one-third of the total proteome is synthesized on the ER.  As a 
protein-folding compartment, this organelle is sensitive to alterations in homeostasis (51-55).  
Multiple physiological or pathological disturbances that cause ER calcium depletion, 
nutrient deprivation, oxidative stress, viral infection or DNA damage can interrupt the 
protein-folding process and trigger accumulation of unfolded or misfolded proteins in the 
ER, a cellular condition referred to as ER stress (56-58).  Under such stress the cell initiates 
a protective mechanism termed the unfolded protein response (UPR) that is specifically 
designed to restore homeostasis and normal ER function.  The UPR consists of three main 
signaling systems initiated by three ER resident stress sensors: activating transcription 
factor 6 (ATF6), inositol requiring kinase 1 (IRE1), and protein kinase R (PKR)-like 
8 
endoplasmic reticulum kinase (PERK) (figure 1.3) (59-61).  Activation of the UPR leads to 
adaptation or cellular death (62).  During adaptation, the UPR functions to restore ER 
homeostasis by inducing the expression of chaperones that enhance protein folding.  At the 
same time, protein translation is globally attenuated to reduce the ER folding load, while 
the degradation of unfolded proteins is increased.  On the contrary, if ER stress is prolonged 
and severe, UPR signaling triggers cell death by apoptosis (63, 64).  Thus, ER homeostasis 
strongly influences many physiological processes including lipid and cholesterol 
metabolism, energy control and inflammation.  The functional significance of UPR 
signaling is not yet fully understood, but it is known that aberrant protein folding and the 
UPR have been linked to the development of various disease states such as diabetes, cancer 
and neurodegenerative disorders (49, 51, 52, 54, 58, 65-69).  Therefore, targeting UPR signaling 
could be a promising therapeutic strategy for the treatment of diseases whose pathogenesis 
is characterized by a highly activated UPR and ER stress.   
Under normal, unstressed conditions, the luminal domains of three UPR sensors 
(ATF6, IRE1 and PERK) are bound to a chaperone called the glucose regulating protein 
78 (GRP78) also known as BiP (70, 71).  However, upon ER stress, GRP78 is released from 
all three transducers and binds to unfolded or misfolded proteins in the lumen of the ER, 
leading to activation of the UPR and downstream signaling events initiated by all three 
UPR transducers.  As mentioned above, if the ER stress is too severe to be handled, the 
UPR initiates apoptotic cell death signaling.  ER sensor molecules including PERK are 
responsible for both the adaptive and the proapoptotic pathways of the UPR.   
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ER stress and UPR signaling are frequently up-regulated in tumor cells as a result 
of mutant or deregulated protein synthesis and folding (72, 73).  They are also up-regulated 
as a consequence of tumor hypoxia promoted by the tumor’s abnormal vasculature, and in 
some cases due to the protein-damaging effects of agents used in chemotherapy (74, 75).  All 
of these may lead to the accumulation of misfolded proteins in the ER (76).  It has been 
reported that the UPR attenuates overall tumor protein translation, while enhancing the 
translation of stress survival proteins such as HIF-1α, c-Myc and VEGF, which are known 
oncoproteins (77-83).  However, how UPR activation contributes to tumor cell survival is not 
clear.   
 
1.5 PERK AND ITS REGULATION 
PERK is an ER transmembrane protein that consists of a luminal domain (bound 
by the ER chaperone BiP/GRP78 under non-stressed conditions) and a cytoplasmic domain 
(that possesses kinase activity).  PERK is a serine-threonine kinase that belongs to the 
eIF2α kinase subfamily (PKR [protein kinase double-stranded RNA-dependent], GCN2 
[general control non-derepressible-2] and HRI [heme-regulated inhibitor]) and 
phosphorylates eIF2α on Ser51 (59, 84-87).  When the ER is stressed, BiP/GRP78 binds to the 
unfolded proteins and releases the luminal domain of PERK, allowing it to oligomerize in 
ER membranes.  This leads to its autophosphorylation and kinase domain activation (61, 88-
90).  The close vicinity of the cytoplasmic kinase domains of the PERK dimer allows trans-
autophosphorylation at multiple sites, including residues on the kinase activation loop and 
the insert loop.  PERK is also capable of undergoing autophosphorylation on its tyrosine 
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residues both in vitro and in vivo (91).  Furthermore, it has been shown that Tyr615, which 
is located in a highly conserved region of the kinase domain of PERK, is essential for 
autocatalytic activity (91).  PERK is known to be hyperphosphorylated by ER stress in cells; 
however, very little is known about where the multiple phosphorylation occurs within its 
kinase domain and how its function is controlled.  Using a chimeric FV2E-PERK construct, 
Avivar-Valderas et al. have demonstrated in vitro that dimerization is sufficient to activate 
the kinase (92).  Recently, a crystal structure of the mouse PERK kinase domain was 
determined to 2.8A resolution, and its structure revealed a back-to-back N-lobe dimer, 
which has been shown for the other eIF2α kinases, GCN2 and PKR (93).   
The activation of PERK results in the phosphorylation of its main downstream 
effector, the eukaryotic initiation factor 2α (eIF2α) and suppression of global mRNA 
translation by inhibiting its GDP-GTP exchange reaction (90, 94).  This mechanism expedites 
the process of ER homeostasis, by enabling the existing unfolded or misfolded proteins in 
the lumen to attain their folded conformation.  Interestingly, attenuated protein translation 
is not universal; genes with internal ribosome entry site (IRES) sequences in the 5′ 
untranslated regions escape from this global inhibition of protein synthesis (95, 96).  
Therefore, some selected mRNAs, such as activating transcription factor 4 (ATF4), are 
translated.  ATF4 acts as a transcription factor regulating multiple genes that contribute to 
recovering ER functions such as amino acid transport and synthesis, redox reactions and 
protein secretion (97, 98).  ATF4 also induces the expression of genes related to pro-apoptotic 
functions.  Two main target genes driven by ATF4 are CHOP (transcription factor C/EBP 
homologous protein) and GADD34 (growth arrest and DNA damage-inducible 34) (99, 100).  
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CHOP is a transcription factor that is associated with apoptotic cell death.  However, the 
link between CHOP expression and cell death is likely more complex than simple down-
regulation of pro-survival genes.  GADD34 encodes a protein phosphatase 1 (PP1) which 
counteracts PERK by dephosphorylating the Ser51 residue of eIF2α (101).  In addition, 
PERK was also reported to phosphorylate the bZIP transcription factor NF-E2 related 
factor 2 (NRF2), resulting in the activation of genes related to antioxidant response 
including heme oxygenase 1 and glutathione S-transferase (102, 103).   
PERK has also been reported to have UPR-independent roles.  It regulates 
proliferation of the insulin-secreting beta cells during early neonatal development and is 
essential for survival of acinar cells in mouse exocrine pancreas, neither of which is 
associated with the ER stress response (104, 105).  The importance of PERK in this response 
was first recognized in the human genetic disorder, Wolcott-Rallison syndrome, which is 
characterized by postnatal retardation, skeletal dysplasia and early onset insulin-dependent 
diabetes (106).  PERK is also required for normal ER functions including pro-insulin 
trafficking, insulin secretion and quality control of protein synthesis in beta cells (106-109).   
Taken together, the PERK-eIF2α arm of the UPR is strongly protective at modest 
levels of signaling (varies depending on cell type) by maintaining redox balance during ER 
stress through activation of ATF4 and NRF2, but can also contribute to apoptotic cell death 
pathways when activated to a greater extent.   
 
1.6 PERK: A KEY MOLECULE OF THE UPR AS A CANCER DRUG TARGET 
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The regulation of protein translation is complex, involving 9 eukaryotic initiation factors 
(eIFs) (110).  Eukaryotic translation initiation factor 2 (eIF-2), which consists of three 
subunits (α, β and γ), is one of the key molecules in the initiation of translation (87, 111).  A 
critical control point is the initiation of protein translation through the alpha subunit of 
elF2, which is required for the recruitment of the methionyl-tRNA to the 40S ribosome at 
the beginning of protein translation.  During the initiation phase, elF2 forms a ternary 
complex with Met-tRNAmet and GTP and facilitates generation of 43S preinitiation 
complex.  Before the joining of the 60S ribosomal subunit, the GTP bound to elF2 is 
hydrolyzed, then elF2-GDP is released from the ribosomal subunit.  For subsequent rounds 
of translation, GDP bound to elF2 must be exchanged for GTP, a process carried out by 
elF2B.  When eIF2 is phosphorylated, it prevents the GDP-GTP exchange activity of 
eIF2B, thus preventing the initiation of protein synthesis, which leads to attenuation of 
general cap-dependent protein translation (87, 112, 113).  In the UPR signaling, the primary 
mechanism for elF2α phosphorylation is through PERK (61, 88).  It has been shown that 
elF2α phosphorylation is associated with increased expression of stress response proteins 
(HIF-1α, c-MYC, VEGF) (114).  Rapidly proliferating cancer cells need increased ER 
activity to facilitate protein folding, assembly and transport.  However, growing tumors 
suffer from regions of hypoxia and from decreased nutrient supply due to abnormal 
vascularization and rapid growth (76, 115).  These changes disturb ER homeostasis and 
activate the UPR to overcome stresses by increasing transcription of stress response genes.  
Thus, in response to ER stress, it was observed that the UPR is activated in a variety of 
tumor types such as cervical carcinoma, glioblastoma, lung cancer and breast cancer from 
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both patients and animal models (57, 116).  Cells with a compromised PERK-eIF2α-ATF4 
signaling pathway are more sensitive to hypoxic stress in vitro, and form tumors that grow 
more slowly in vivo (117).  Previous studies by Blais et al. demonstrate that tumors derived 
from K-Ras-transformed Perk−/− mouse embryonic fibroblasts (MEFs) are not only smaller 
than wild-type tumors but also appear to have severe limitations in their ability to stimulate 
tumor cell adaptation and angiogenesis (80, 118).  Similarly, cell-cycle arrest was observed 
when PERK expression was knocked down by shRNA in human breast cancer cells and 
esophageal carcinoma cells.  In addition, BiP, a regulator of PERK, was also shown to be 
required for both tumor growth and conferring drug resistance (119).   
Poor oxygenation (hypoxia) is present in the majority of human tumors and is 
associated with poor prognosis (74, 115).  Hypoxia also elicits multiple cellular response 
pathways that alter gene expression and affect tumor progression, including two separate 
pathways that strongly suppress the mRNA translation during hypoxia (74, 120).  The first 
pathway is mediated by the UPR and phosphorylation of the eIF2α, which is required for 
hypoxic cell survival and tumor growth.  Translation during hypoxia is also inhibited 
through the inactivation of a second eukaryotic initiation complex, eukaryotic initiation 
factor 4F (115).  At least part of this inhibition is mediated through the mammalian target of 
rapamycin kinase (mTOR).  mTOR integrates signals from several upstream pathways that 
respond to growth factors, nutrients, and energy, to regulate metabolism and cell growth 
(120-123).  Control of mRNA translation via disruption of eIF4F is indeed expected to vary 
considerably among different tumors because the upstream pathways that control the 
assembly of this complex are frequently disrupted in cancer (120).  In addition, eIF4F has 
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emerged as an important target during tumor development.  Although eIF4F assembly 
under hypoxia is disrupted, the importance of this effect on tumor growth or hypoxia 
tolerance has yet to be addressed.   
Despite PERK being identified as a therapeutic target for cancer, no selective 
inhibitors had been reported when this study began.  However, recently GlaxoSmithKline 
research group reported a highly specific small molecule inhibitor of PERK (GSK2606414) 
(124).  GSK2606414 is a high affinity ligand of the PERK kinase domain that hinders kinase 
activity by binding to the kinase ATP binding pocket, resulting in competition with ATP.  
GSK2606414 inhibited PERK activation in A549 cells and decreased tumor growth in a 
xenograft model of pancreatic cancer at a dose of 50-150 mg/kg per day.  The same group 
developed a further optimized PERK inhibitor, GSK 2656157 (125), which also blocked 
PERK activity in cells as shown by a decrease in PERK autophosphorylation, eIF2α 
phosphorylation, expression of ATF4 and CHOP.  Twice daily oral administration of 
GSK2656157 also inhibited tumor growth in several mouse xenograft models.  Using in 
vivo techniques, including gene expression analysis in pancreatic tumor xenografts and 
immunohistochemistry, Axten et al. showed that the anticancer activity of the PERK 
inhibitor (GSK 2656157) correlates with several physiological features including altered 
amino acid metabolism, decreased blood vessel density, and vascular perfusion (125).  
However, mechanisms for the observed anti-tumor effect need to be further elucidated.   
Together, this evidence suggests a substantial role for PERK and the UPR in tumor 
survival and adaptation to stress.  Therefore, inhibiting PERK activity offer a potentially 
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effective approach to block the UPR and thus, the synthesis of stress survival oncoproteins, 





Figure 1.1. Schematic structure of TRPM7 channel.   
Representation of the domain structure of TRPM7 including the six transmembrane 
domain, coiled-coil domain, Ser/Thr-rich region and the atypical alpha-kinase domain. 
(Modified from Wolf et al. (10))  
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Figure 1.2. Crystal structure of TRPM7.  
A, Structure of the TRPM channel coiled-coil assembly domain (Fujiwara et al.)(22)  





Figure 1.3. Schematic representation of ER stress-induced unfolded protein response 
(UPR).  
Accumulation of misfolded or unfolded proteins at the ER triggers an adaptive stress 
response known as the UPR.  The UPR is controlled by three sensors molecules of unfolded 
proteins in the ER membrane (ATF6, PERK, and IRE1).  The ER stress sensors activate 
transcriptional and translational programs that collectively recover the homeostasis of 
protein folding in the ER.   
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Chapter 2: Characterization of the Mechanism of TRPM7 




The channel-kinase TRPM7 is a bifunctional protein consisting of a cation channel 
that is permeable to Mg2+, Ca2+ and Mn2+ and is fused to a kinase domain.  
Electrophysiological characterization of TRPM7 implicates it in cellular magnesium 
homeostasis.  While the channel properties of TRPM7 have been studied extensively, little 
is known about the mechanisms regulating its kinase activity.  In this study, we investigated 
the biochemical and functional properties of TRPM7 autoactivity.  The vigorous 
autophosphorylation of the TRPM7 kinase domain during its expression in bacterial cells 
acted as a barrier towards the study of its mechanism of autoactivation.  The use of a lambda 
phosphatase co-expression protocol enabled us to obtain phosphate-free TRPM7.  Using 
this form of TRPM7, we could monitor its autophosphorylation and relate it to its activity 
against a downstream substrate.  Here, using rapid quench-flow kinetics, we demonstrate 
that the first three phosphates that add to the enzyme (in the first ~30 seconds) are sufficient 
to fully active TRPM7 against a peptide substrate and myosin.  These three sites were 
determined by mass spectrometry.  Mutation of the three early autophosphorylation sites 
                                                 
† Contributions to the work described in this chapter: Dr. Tamer S. Kaoud (Analyzed PF-TRPM7 by rapid 
quench flow device and helped fitting kinetic data); Dr. James A. Madsen and Dr. Jennifer S. Brodbelt 
(Analyzed early autophosphorylation sites of TRPM7 by mass spectrometry); Dr. Austen F. Riggs (Analyzed 
TRPM7 by dynamic light scattering). 
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abolished kinase activity against its substrates and impeded its interaction with actomyosin 
in the cells.  To study the effect of oligomerization of the kinase domain on the 
autophosphorylation of TRPM7, rapid quench flow was employed over a range of TRMP7 
concentrations.  The rate of autophosphorylation increased steadily with increasing 
concentration, consistent with oligomerization-dependent autophosphorylation.  
Phosphate-free TRPM7 kinase domain exists as a tetramer, while both fully activated and 
transiently-autophosphorylated (30 seconds) TRPM7 kinase domain is dimeric.  
Collectively, our results support a model where early autophosphorylation on three 
residues triggers a conformational change that promotes a tetramer to dimer transition of 




The channel-kinase TRPM7 is ubiquitously expressed.  This channel is permeable 
to various cations such as Mg2+, Ca2+, Zn2+, Co2+and Mn2+, but preferentially transports 
Mg2+ (12, 126, 127).  Since Mg2+ is an abundant and essential divalent ion in the cell (126), 
TRPM7 is considered to be an important regulator of cellular Mg2+ homeostasis (6, 8).  
Magnesium is a critical cation and cofactor in various intracellular functions where it 
provides structural integrity for numerous proteins and nucleic acids and is a cofactor for 
many enzymatic reactions (126).  However, little is known about the regulation of cellular 
Mg2+ homeostasis.  Recent studies showed that homozygous deletion of the kinase domain 
caused embryonic lethality while heterozygous mice displayed abnormal absorption of 
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Mg2+ suggesting that TRPM7 is a key regulator of Mg2+ homeostasis (24).  On the other 
hand, another study using primary mammalian cells reported that deletion of the gene 
Trpm7 did not affect the absorption of Mg2+ or the concentration of total cellular Mg2+  (128).  
The functional alpha-kinase domain at the carboxyl terminus of TRPM7 has been 
structurally characterized and displays the unique feature of a zinc finger domain as well 
as a region involved in the binding of ATP (32).  The bifunctional property of TRPM7 to 
act as an ion channel and as a kinase provides this protein unique abilities to regulate 
cellular signal transduction (6, 8).  The role of the TRPM7 kinase domain in the channel 
function remains controversial.  While some studies reported that the TRPM7 channel 
activity is dependent on the phosphotransferase activity of the kinase domain by showing 
for example that mutations of the kinase domain disrupted the channel function in whole 
cell recordings, others found that the channel function was dissociated from the kinase 
activity by demonstrating that TRPM7 lacking the kinase domain exhibited the same Mg2+ 
sensitivity as wild type TRPM7 (6, 14, 31, 129).  Three downstream substrates of TRPM7 kinase 
have been identified so far.  These are annexin-1, myosin II, and calpain (37, 38, 130). 
Besides a role in Mg2+ homeostasis, TRPM7 is involved in other cellular events 
such as cell proliferation, apoptosis, exocytosis, cell adhesion and actomyosin contractility 
(2, 26, 36-38, 130).  Considering that these substrates and TRPM7 have been implicated in cell 
migration, cell growth, and cell death, it is possible that the phosphorylation of annexin-1, 
myosin II, or calpain by the TRPM7 kinase domain is involved in the regulation of cell 
survival and cell death.  However, the biological importance of these signaling events still 
remains to be addressed.  Recent studies suggested that the TRPM7 kinase domain 
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autophosphorylates extensively (more than 30 sites) within its C-terminus and this 
extensive autophosphorylation controls substrate recognition and phosphorylation (34).  In 
addition, it was reported that dimerization of TRPM7 is required for its activity (32, 33).  To 
date, little is known regarding the role of autophosphorylation in regulating TRPM7 kinase 
activity.  According to a growing number of studies with clinical significance, TRPM7 has 
been linked to the pathogenesis of human diseases such as ischemic brain damage, 
Alzheimer’s disease, stroke and cancer (1, 39, 41, 131, 132).  Protein kinases are important targets 
for the treatment of human diseases such as cancer as they are often the result of 
misregulated kinase-dependent signaling pathways (133-136).  Hence TRPM7 can be a 
candidate target for the treatment of human disease. 
In this study, we characterized the mechanisms of TRPM7 autophosphorylation 
using purified nonphosphorylated TPRM7 catalytic domain and its activity against 
downstream substrates.  We used both peptide and myosin as substrates.  A rapid quench-
flow kinetic study of its autophosphorylation and autoactivation revealed that the first three 
phosphates added to the enzyme (within the ~30 seconds) are enough to make the enzyme 
fully active against its peptide substrate, while the remaining 34 phosphates that are added 
by further autophosphorylation are not required for its activity.  These three 
autophosphorylation sites have been further studied by MS/MS and site-directed 
mutagenesis.  To study the effect of oligomerization on autophosphorylation of TRPM7, 
rapid quench-flow was employed to determine the ability of TRPM7 to be 
autophosphorylated at different concentrations.  At a concentration of more than 400 nM 
the rate of TRPM7 autophosphorylation plateaued.  In order to monitor the active state of 
23 
this enzyme, dynamic light scattering was used.  We also performed a pre-steady state 
kinetic analysis of the enzyme to obtain the catalytic properties of TRPM7 in detail.  We 
observed an initial burst followed by slower, linear phase.  Overall, our results provide a 
detailed characterization of the kinase activity of TRPM7 and suggest that TRPM7 is 
autophosphorylated in an oligomerization-dependent manner and requires no more than 
three phosphates to become active towards other substrates.  The autophosphorylation on 
three sites may play a role promoting a conformational change necessary for enzyme 
activity and may communicate to regulate the channel. 
 
2.3 MATERIALS AND METHODS 
Reagents, Strains, Plasmids and Equipment 
Yeast extract, tryptone and agar were purchased from USB Corporation (Cleveland, 
OH). Isopropyl β-D-1-thiogalactopyranoside (IPTG) and dithiothreitol (DTT) were 
obtained from US Biological (Swampscott, MA).  Qiagen (Valencia, CA) supplied Ni-
NTA Agarose, QIAprep Spin Miniprep Kit, QIAquick PCR Purification Kit and QIAquick 
Gel Extraction Kit. Restriction enzymes, PCR reagents and T4 DNA Ligase were obtained 
from either New England BioLabs (Ipswich, MA) or Invitrogen Corporation (Carlsbad, 
CA).  Oligonucleotides for DNA amplification and mutagenesis were from Sigma-Aldrich 
(St. Louis, MO).  Stratagene PfuUltra™ High-Fidelity DNA Polymerase was purchased 
from Agilent Technologies, Inc. (Santa Clara, CA).  BenchMark™ Protein Ladder was 
from Invitrogen Corporation.  SIGMAFASTTM Protease inhibitor cocktail tablets for 
purification of His-tagged proteins, ultra-pure grade Tris-HCl, and HEPES were from 
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Sigma-Aldrich.  All other buffer components or chemicals were purchased from either 
Sigma-Aldrich or Fischer Scientific (Pittsburgh, PA).  Amicon Ultrafiltration Stirred Cells, 
Ultracel Amicon Ultrafiltration Discs and Amicon Ultra Centrifugal Filter Units were from 
Millipore (Billerica, MA).  ATP was purchased from Roche (Indianaoilus, IN) and [γ-32P] 
ATP was purchased from Perkin Elmer (Waltham, MA).  E. coli strain DH5a for cloning 
was obtained from Invitrogen Corporation, and BL21 (DE3) and Rosetta-gami™ 2(DE3) 
for recombinant protein expression were from Novagen, EMD4Biosciences (Gibbstown, 
NJ).  The pET-32a vector was obtained from Novagen.  The ÄKTA FPLC™ System and 
the following columns Mono Q HR 10/100 anion exchange column and Superdex™ 200 
prep grade gel filtration column were from Amersham Biosciences GE Healthcare Life 
Sciences (Piscataway, NJ). 
 
Constructs 
1) Construction of pET32a-TRPM7 1403-1864 : A construct encoding the Trx-
His6-tagged kinase domain of TRPM7 was created by PCR amplification of the nucleotide 
sequence corresponding to the last 462 amino acids (1403-1864) of Homo sapiens channel-
kinase 1 (CHAK1, GenBankTM accession number AF346629) using the following 
oligonucleotides: forward (5’-
CCGGAATTCATGGCGGCGTCCTCCCTGGAGCAGAAG-3’) and reverse (5’-
ATGCGGCCGCTCTCAGTGATGATGATGATGATGGGATCCACGCGGAACCAGC
CTGAAGAAGGGCAGATGGTGCTG-3’).  The PCR product was digested with EcoRI 
and NotI, and the resulting digested product was ligated into an EcoRI-NotI digested 
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pET32a vector that has been modified by replacing the sequence coding for the 
enterokinase cleavage site by the TEV protease cleavage recognition sequence.  Then, the 
construct was transformed into the E. coli strain DH5.  Plasmid DNA was purified and 
the sequence verified by sequencing.   
2) Construction of pGEX4T-myosin1802-1977: 
DNA encoding human nonmuscle myosin heavy chain II B in the CMV-EGFP vector was 
obtained from Addgene (Cambridge, MA).  Human myosin heavy chain II B (aa 1802-
1977) was created by PCR amplification using the following oligonucleotides, a) forward 
(5’- GGCAGCGGAGGGATGCAGGAACTCGAG-3’) and b) reverse (5’-
GACCCAGAGCCACCTTACTCTGACTGGGGTGG-3’) and the PCR product was 
ligated into the linearized pGEX4T-1 vector.  Then, the construct was transformed into the 
E. coli strain DH5. Plasmid DNA was purified and the sequence verified by sequencing.   
3) Construction of mutant TRPM7:  
A PCR based site-directed mutagenesis method was employed to generate point mutants, 
S1492A, S1511A, S1567A, S1492D, S1511D, and S1567D.  The wild type pET32a-
TRPM7 construct was used as a template, and PCR was carried out for each mutant with a 
set of sense and antisense mutagenic primers.  The PCR products were treated with Dpn1 
restriction enzyme and purified through DNA agarose gel electrophoresis.  Purified DNA 
was used to transform E. coli strain (Novablue), and transformants were identified. 
Mutations were confirmed by DNA sequencing. 
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Expression and Purification of Proteins in E.coli 
1) Expression and purification of phosphate-free TRPM7 (PF-TRPM7):  
The TRPM7 catalytic domain was undergoing autophosphorylation intensively, which was 
indicated by a relatively high molecular mass shown on the SDS-PAGE gel (~90 kDa) 
compared with its actual molecular mass ~73 kDa.  The unphosphorylated TRPM7 
catalytic domain was prepared by co-expressing with lambda phosphatase, and the plasmid 
pCDF-Duet λ-phosphatase was given as a generous gift from Dr.Richard Bayliss (Institute 
of Cancer Research, London UK).  The constructs, pET32a-Trx-TRPM7 and pCDF-Duet 
λ-phosphatase were co-transferred into E. coli strain C41 (DE3).  A single colony of freshly 
transformed cells was used to inoculate 100 mL of Luria-Bertani (LB) media containing 
50 g/mL ampicillin, 17 g/mL chloramphenicol, and 5 g/mL spectinomycine, and 
grown overnight at 37 ˚C on a shaker (250 rpm).  The culture was diluted 100-fold into 2x 
YT media containing the same concentration of antibiotics and incubated at 37 ˚C on a 
shaker (250 rpm) until it reached an OD600 of 0.6-1.0.  Protein expression was then induced 
with 20µM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 16 hours at 22 ̊ C.  The cells 
were harvested by centrifugation (6000g for 10 minutes at 4 ˚C), flash frozen in liquid 
nitrogen and stored at -80 ˚C.  The collected cells were lysed in 150 mL of buffer A (20 
mM Tris pH 8.0, 0.03% Brij-30, 0.1% (v/v) β-mercaptoethanol, 5 mM imidazole, 1mM 
benzamidine, 0.1 mM PMSF, and 0.1 mM TPCK) containing 0.5 M NaCl, 20% glycerol, 
1 mM MgCl2 and 0.2 mg/ml lysozyme at 4 °C for 30 minutes.  The suspension was 
sonicated for 10 minutes (5 s pulses) at 4 ºC.  The lysate was cleared by centrifugation 
(Sorvall – SS34 rotor) at 27,000g for 30 minutes at 4 ̊ C and the supernatant gently agitated 
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with 15 mL of Ni-NTA beads (Qiagen) for 1 hour at 4 ˚C.  In a 100 mL chromatography 
column, the beads were washed with 150 mL of buffer A containing 10 mM imidazole and 
the Trx-His6-TRPM7 was then eluted with 30 mL of Buffer A containing 200 mM 
imidazole.  The eluted protein was applied to a Mono Q HR 10/10 anion exchange column 
equilibrated in buffer B (20 mM Tris pH 8.0, (v/v) 0.03% Brij-30, (v/v) 0.1% β-
mercaptoethanol, and 20% glycerol).  The column was developed over 15-17 column 
volumes of buffer B with a linear gradient of 0-0.5 M NaCl.  Eluted fractions of Trx-His6-
TRPM7 were collected and concentrated to a volume of 10 mL using an Amicon Ultra-15 
Centrifugal Filter Unit (Millipore) and applied to a HiLoad™ 16/60 Superdex™ 200 prep 
grade gel filtration column pre-equilibrated with Buffer D (25 mM HEPES, 2 mM 
dithiothrietol, 20 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, and 20% glycerol pH 7.5).  
Gel filtration chromatography was performed over 1.5 column volumes (180 mL) at a flow 
rate of 1 mL/min.  Fractions were collected and analyzed for purity using SDS-PAGE.  
Fractions that contained the TRPM7 catalytic domain were pooled and dialyzed against 
Buffer E (25 mM HEPES pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM 
DTT, and 10 % glycerol)  
2) Expression and purification of fully phosphorylated TRPM7 kinase domain 
(TRPM7-KD): 
The construct, pET32a-Trx-TRPM7 was transferred into E. coli strain Rosetta-gami™ 
2(DE3).  A single colony of freshly transformed cells was used to inoculate 100 mL of 
Luria-Bertani (LB) media containing 50 g/mL ampicillin, 17 g/mL chloramphenicol, 
and 5 g/mL tetracycline, and grown overnight at 37 ̊ C on a shaker (250 rpm).  The culture 
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was diluted 100-fold into 2x YT media containing the same concentration of antibiotics 
and incubated at 37 ˚C on a shaker (250 rpm) until it reached an OD600 of 0.6-1.0.  
Purification step was same as the one for PF-TRPM7.  
3) Expression and purification of GST myosin heavy chain II B (1802-1977): 
pGEX 4T1 containing DNA encoding residues 1802-1977 of myosin heavy chain II B was 
transformed into E. coli strain BL21 (DE3) electro-competent cells.  From a single colony 
of freshly transformed cells, a 10 mL culture of LB containing 50 μg /mL ampicillin was 
inoculated and incubated with shaking overnight at 37 ºC.  The culture was diluted 100-
fold into LB media containing 50 μg/ mL ampicillin, and incubated at 37 ºC with shaking.  
Once the OD600 of the culture had reached 0.6, the expression was induced by the addition 
of 1 mM IPTG. Shaking was continued at 37 ºC for 1 hour, before the cells were pelleted 
(7000×g, 12 minutes).  The bacterial pellets were immediately frozen in liquid nitrogen 
and stored at -80 ºC.  The frozen wet cells were resuspended in 50 ml of Buffer F (10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.3, 140 mM NaCl, 2.7 mM KCl, 0.1% β-mercaptoethanol, 
0.1 mM TPCK, 0.1 mM PMSF and 1 mM Benzamidine) containing 0.2 mg/mL lysozyme.  
The mixture was incubated at 4 ºC for 30 minutes.  Then Triton X-100 was added (to a 
final concentration of 1%) and incubated another 30 minutes at 4 °C. Finally, the cells were 
sonicated for 5 minutes at 4 °C.  The lysate was then centrifuged for 30 minutes at 
12,000×g.  The supernatant was mixed with 10 mL of Glutathione Sepharose™ High 
Performance (Amersham Biosciences) equilibrated in Buffer E and shaken gently for 1.5 
hours at 4 ºC.  In a 50 mL column, the beads were washed with 50 mL of Buffer E.  The 
GST-tagged proteins were eluted with 5 mL buffer G (50 mM Tris HCl pH 7.5 containing 
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20 mM reduced glutathione, 0.1% β-mercaptoethanol, 0.1 mM TPCK, 0.1 mM PMSF and 
1 mM Benzamidine). 
 
Analytical Methods 
General kinetic assays 
In order to assess the correlation between PF-TRPM7 autophosphorylation and its 
kinase activity, autophosphorylation and activity towards peptide substrate were measured 
concurrently. After initiating 800 nM PF-TRPM7 autophosphorylation by adding 1 mM 
[-32P] ATP (100-1000 cpm/pmol), the degree of autophosphorylation was determined in 
10 μl aliquots that were taken from the reaction mixture at set time points. Concurrently, 
aliquots (30 μl) from the TRPM7-KD autophosphorylation reaction mixture were diluted 
and its ability to phosphorylate its peptide substrate was determined. 
TRPM7-KD activity was assayed at 30 °C in assay buffer (25 mM HEPES buffer-
pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT and 10 μg mL-1 BSA), 
containing 300 μM [γ-32P] ATP (100-1000 c.p.m. pmol-1), 11 mM MgCl2 and 12.5µM of 
peptide substrate (acetyl-RKKYRIVWKSIFRRFL-amide) in a final total volume of 100 
µL.  At set time points, 10 L aliquots were taken and spotted onto P81 cellulose filters 
(Whatman, 2 × 2 cm).  The filter papers were then washed thrice in 50 mM phosphoric 
acid (15 minutes, each wash), once in acetone (15 minutes) and finally dried.  The amount 
of labeled peptide associated with each paper was determined by measuring the cpm on a 
Packard 1500 scintillation counter.   
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Autophosphorylation assay using rapid quench flow equipment 
Rapid Chemical Quench. Rapid quench experiments were performed on a KinTek RQF-3 
rapid quench-flow apparatus. reactions were conducted at 27 ºC in assay buffer (25 mM 
HEPES, 50 mM KCl, 2 mM DTT, 0.1 mM EDTA, and 0.1 mM EGTA, pH 7.4) containing 
10 mM MgCl2. Experiments were initiated by the rapid mixing of solution A (containing 
2 mM [-32P] ATP (100-1000 cpm/pmol) with an equal volume of solution B (containing 
various concentrations PF-TRPM7 0-6400 nM). After brief time intervals (0.02-40 
seconds), reactions were quenched with 115 μL of quenching buffer (20 mM HEPES pH 
7.4, 200 mM KCl, 0.1% bovine serum albumin, 50 mM EDTA, 1 mM EGTA). The 
quenched reaction mixture was collected in 1.5 mL centrifuge tubes followed by heating 
for 10 minutes at 95 ˚C and centrifuged briefly at 5000g.  Aliquots (30 μL) of the quenched 
reaction mixture were resolved by SDS-PAGE and stained with Coomassie Brilliant Blue.  
Gels were exposed for 16 hours in a Phosphorimager cassette which was then scanned in a 
Typhoon Phosphorimager and then analyzed using ImageQuant™ TL software.  To 
determine the stoichiometry of the autophosphorylation, the gels were dried, the pieces 
containing TRPM7-KD excised, and the associated radioactivity measured with a Packard 
1500 liquid scintillation analyzer. 
Pre-steady state kinetic assay 
Rapid quench experiments were performed on a KinTek RQF-3 rapid quench-flow 
apparatus. reactions were conducted at 27 ºC in assay buffer (25 mM HEPES, 50 mM KCl, 
2 mM DTT, 0.1 mM EDTA, and 0.1 mM EGTA, pH 7.4) containing 10 mM MgCl2. 
Experiments were initiated by the rapid mixing of solution A (containing 2 mM [-32P] 
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ATP (100-1000 cpm/pmol) and 25 μM peptide substrate mixture) with an equal volume of 
solution B (containing either 1600 nM fully phosphorylated TRPM7-KD [figure 2.5] or 
1600 nM PF-TRPM7 [figure2.3B]). After brief time intervals (0.01-4 seconds), reactions 
were quenched with 115 μL of quenching buffer (20 mM HEPES pH 7.4, 200 mM KCl, 
0.1% bovine serum albumin, 50 mM EDTA, 1 mM EGTA).  The quenched reaction 
mixture was collected in 1.5 mL centrifuge tubes followed by heating for 10 minutes at 95 
˚C and centrifuged briefly at 5000g.  Aliquots (30 μL) of the quenched reaction mixture 
were resolved by 20% SDS-PAGE and stained with Coomassie Brilliant Blue.  Gels were 
exposed for 16 hours in a Phosphorimager cassette which was then scanned in a Typhoon 
Phosphorimager and then analyzed using ImageQuant™ TL software.  To determine the 
peptide substrate phosphorylation, the gels were dried, the pieces containing 
phosphorylated peptide excised, and the associated radioactivity measured with a Packard 
1500 liquid scintillation analyzer.  In experiments where both PF-TRPM7 
autophosphorylation and peptide substrate phosphorylation were monitored 
simultaneously (figure 2.6A), the gels were dried, the pieces containing either 
autophosphorylated TRPM7-KD or phosphorylated peptide excised, and the associated 
radioactivity measured with a Packard 1500 liquid scintillation analyzer. 
Analysis of the three autophosphorylation-site mutants.   
a. Assay against peptide substrate: Assays were performed in the assay buffer (25 
mM HEPES, 50 mM KCl, 2 mM DTT, 0.1 mM EDTA, and 0.1 mM EGTA, pH 7.4) 
containing 10 mM MgCl2 using 80 nM of TRPM7-KD WT and mutants that were pre-
autophosphorylated following the protocol that mentioned in the general kinetics assays, 
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12.5 μM peptide substrate and 0.5 mM [-32P] ATP (100-1000 cpm/pmol) in a final 
reaction volume of 100 L.  Kinase activity in each case was determined by calculating the 
rate of phosphorylation of the peptide.  b. Assay against myosin IIB: Assays were 
performed in the same assay buffer mentioned above using 80 nM of TRPM7-KD WT and 
mutants, 8 μM myosin IIB and 1 mM [-32P] ATP (100-1000 cpm/pmol) in a final reaction 
volume of 50 L.  The reaction mixture was incubated at 30 ˚C for 10 minutes before the 
reaction was initiated by addition of 1 mM [-32P] ATP.  The reaction was carried out for 
1 minute and quenched by addition of hot SDS-PAGE sample loading buffer.  The samples 
were resolved by SDS-PAGE and stained with Coomassie Brilliant Blue.  Gels were 
exposed for 2 hours in a phosphorimager cassette which was then scanned in a Typhoon 
Phosphorimager.  c. Autophosphoylation of TRPM7-KD mutants: Assays were performed 
in the same assay buffer described earlier using 800 nM TRPM7-KD mutants and 1 mM 
[-32P] ATP (100-1000 cpm/pmol) in a final reaction volume of 50 L.  The reaction 
mixture was incubated for 30 and 60 minutes.  The samples were analyzed as mentioned 
above. 
 
Dynamic Light scattering 
Dynamic light scattering experiments were performed on phosphate-freeTRPM7-
KD, 30 seconds autophosphorylated TRPM7-KD and fully phosphorylated TRPM7-KD. 
Samples were previously dialyzed against light scattering assay buffer (25 mM HEPES 
(pH 7.5), 100 mM NaCl, 2 mM DTT and 5 mM MgCl2).  The assay buffer, which is freshly 
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prepared with Nanopure water (~18.3 MΩ cm) and filtered through a 0.02 m filter 
(Anodisc 47, Whatman, catalog # 6809-5002) was used to establish the light scattering and 
refractive index baselines.  The TRPM7-KD sample, 40 μL at 3.6 μM, was centrifuged for 
30 seconds and injected into the column.  Bovine serum albumin monomer (Sigma A1900) 
was injected to the column at 2 mg/mL for normalization of the light-scattering detectors.  
Size exclusion 14 chromatography was performed at a flow rate of 0.4 mL/min at room 
temperature for a run time of ~ 40 minutes.  All measurements were made at 25 C.  Size-
exclusion chromatography was performed as previously described (137, 138) with a TSK-
GEL G3000PWXL column (300 × 7.8 mm ID, 14 mL column volume, Tosoh Bioscience 
LLC).  Samples were centrifuged for ~ 30 seconds to remove any insoluble components 
prior to injection.  Molar masses, peak concentrations and hydrodynamic radii were 
determined with Astra software (Wyatt Technology).   
 
Mass Spectrometry, Liquid Chromatography, and Automated Spectral Analysis 
TRPM7 samples were reduced, alkylated, and digested with trypsin. A 1:20 
enzyme: substrate ratio, a pH of ~8, and an incubation time of 16 hours at 37 °C were used 
for digestion.  All mass spectrometric experiments were undertaken on a Thermo Fisher 
Scientific LTQ XL (San Jose, CA).  Liquid chromatography was performed using a Dionex 
UltiMate 3000 RSLCnano system (Sunnyvale, CA), and a Dionex Acclaim PepMap RSLC 
C18 column (75 μm × 15 cm, 2 μm particle size).  Eluent A consisted of 0.1% formic acid 
in water and eluent B 0.1% formic acid in acetonitrile.  A linear gradient from 5% eluent 
B to 50% eluent B over 120 minutes at 300 nL/min was used.  Samples were injected at 
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approximately one picomole of digested protein.  Data-dependent LC-MS/MS was 
performed as follows: the first event was the full mass scan (m/z range of 400 - 2000) in 
the positive mode followed by ten CID events on the ten most abundant ions from the full 
mass scan.  The maximum injection time for full mass scans and MS/MS events was set to 
100 ms, the dynamic exclusion duration was 50 s, and the exclusion list size allowed for 
500 specified m/z values.  A single repeat count was used. A q-value of 0.25, an activation 
time of 30 ms, and normalized collision energy (NCE) of 35% were used for all CID events.  
MassMatrix was used for automated LC-MS/MS analysis.  A precursor mass tolerance of 
2.0 Da, and a fragment mass tolerance of 0.8 Da were used for processing.  Phosphorylation 
of serine, threonine, and tyrosine were set as variable side-chain modifications, and 
carbamidomethyl of cysteine was set as a fixed modification.  Experimental CID spectra 
were searched against a database consisting of the TRPM7 + tag sequence.  Peptide hits 
were filtered based on a minimum pp score of 5, a pp2 score of 5, or a minimum pptag score 
of 1.3.  Peptides with a minimum length of 6 amino acids and a max peptide ranking of 
one were also filtered out.  Phosphorylated peptides were manually verified before 
calculating peak area ratios. 
 
Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain 
Reaction 
A PCR-based site-directed mutagenesis method was employed to generate point 
mutants, S1492A, S1511A, and S1567A.  The full length WT TRPM7 construct containing 
Myc and FLAG tags (Origene) was used as a template, and PCR was carried out for each 
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mutant with a set of sense and antisense mutagenic primers.  The PCR products were 
treated with DpnI restriction enzyme to get rid of methylated template plasmid and purified 
through agarose gel electrophoresis.  The mutated plasmid remains intact in the reaction.  
Purified DNA was used to transform E. coli (novablue), and transformants harboring 
mutant constructs were identified.  Mutations were confirmed by DNA sequencing. 
 
Western Blotting and Immunoprecipitation Experiments 
The full length of Myc-FLAG tagged TRPM7 in pCMV vector was purchased from 
Origene.  HEK293 cells were transfected with full length of Myc-FLAG tagged TRPM7 
(both WT and alanine mutants) using lipofetamine 2000 (Invitrogen).  At 72 hours after 
transfection, cells were lysed on ice for 20 minutes in lysis buffer (50 mM Tris pH 7.5, 300 
mM NaCl2, 0.5 mM DTT, 1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100 supplemented 
with protease inhibitors) and the extract was cleared by centrifugation.  The protein 
concentration was measured by Bradford analysis (Bio-Rad).  For immunoprecipitation of 
exogenously expressed TRPM7, Myc-Tag (9B11) Mouse mAb (Sepharose Bead 
Conjugate) (Cell Signaling Technology) was added to the lysates of WT and mutant 
TRPM7, the samples were incubated at 4 °C overnight.  Subsequently, the beads were 
washed three times with lysis buffer, protein complexes were solubilized in Laemmli 
sample buffer and separated by SDS-PAGE.  Proteins were fractionated on a 10% SDS 
polyacrylamide gel (Bio-Rad) and transferred to Hybond-P PVDF Membrane (GE 
Healthcare).  Primary antibodies were incubated overnight at 4 ºC using 1:1000 anti-FLAG 
antibody (Sigma-Aldrich); 1:1000 anti-myosin IIB rabbit polyclonal antibodies (Cell 
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Signaling Technology); anti-rabbit (Bio-Rad) horseradish peroxidase-conjugated 
secondary antibodies and ECL Plus™ Western blotting reagents (GE Healthcare) were 
employed to develop the blots. 
 
2.4 RESULTS AND DISCUSSION 
Preparation of phosphate-free TRPM7-KD to facilitate the study of its 
autophosphorylation mechanism  
All alpha-kinases including eEF2K, MHCKs, TRPM6, and TRPM7 have been 
reported to autophosphorylate, and this autophosphorylation is considered to be an 
important regulatory mechanism for their activity (1).  The in vitro study of the 
autophosphorylation mechanism of these enzymes is challenging due to its uncontrollable 
autophosphorylation upon expression in bacterial or mammalian cells.  For example, a 
recent study has shown that the cytosolic C-terminal kinase domain of TRPM7 undergoes 
extensive autophosphorylation during expression in HEK293 cells (34).  Herein, we 
introduced a novel co-expression system to co-express both lambda phosphatase and 
residues 1403-1864 of TRPM7 (TRPM7-KD) in E. coli in order to prepare the phosphate-
free TRPM7 kinase domain (PF-TRPM7).   
The SDS-PAGE experiments shown in figure 2.1A and B demonstrate the 
difference in apparent molecular weight when assessed by SDS PAGE (72 versus 90 kDa) 
between TRPM7-KD when expressed in E. coli, in the presence and absence of lambda 
phosphatase.  When TRPM7-KD is treated with lambda phosphatase in vitro a similar 
molecular weight band is observed supporting the notion that this system can produce 
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phosphate-free TRPM7-KD (PF-TRPM7).  The phosphorylation status of PF-TRPM7 was 
further examined.  A mass spectrometry analysis of proteolytically cleaved PF-TRPM7 
revealed only trace phosphorylation (figure 2.6 B, D).  
To test the capability of PF-TRPM7 to autophosphorylate in vitro after removal of 
the phosphates during bacterial expression, 800 nM of PF-TRPM7 was incubated with 1 
mM [-32P] ATP in the presence of 11 mM MgCl2 and phosphate addition detected by 
autoradiography and quantified by phosphorimager analysis.  PF-TRPM7 was successfully 
autophosphorylated with high efficiency in vitro (figure 2.1C), which validates this form 
of the enzyme as a suitable tool to study the TRPM7-KD autophosphorylation mechanism. 
 
Evidence that the inactive kinase domain is tetrameric 
 A shorter form of TRPM7 (residues 1548-1863) has been reported by Scott W. 
Crawley et al. (33) to be a dimer, while the structure of residues 1230-1282 (TRPM7cc) that 
corresponds to a coiled-coil domain has been recently resolved by Yuichiro Fujiwara et al. 
(22) to be an antiparallel tetramer in both crystal and solution.  The availability of a 
phosphate-free form of the kinase domain TRPM7 enhances the chance to characterize the 
oligomerization state of this domain in both its non-phosphorylated and fully 
phosphorylated form using dynamic light scattering (139).  Figure 2.2 shows that PF-TRPM7 
has an approximate molecular mass that is 4-fold the expected molecular mass (72kDa), 
suggesting that PF-TRPM7 is a tetramer in solution. 
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Autophosphorylation is required to activate TRPM7-KD 
To compare the autoactivation of PF-TRPM7 and TRPM7-KD, we monitored their 
activities towards a peptide substrate (RKKYRIVWKSIFRRFL) (140) utilizing a P81-based 
kinase assay (figure 2.3A).  Kinase activity was measured as a function of 
autophosphorylation time.  The kinase activity of both PF-TRPM7 (figure 2.3A) and 
TRPM7-KD (data not shown) was maximal within the first minute of autophosphorylation, 
suggesting that either autophosphorylation is not required for its kinase activity or the 
autophosphorylation is rapid.   
To test if autophosphorylation is required for its kinase activity, we used a rapid 
quench-flow device to monitor phosphate incorporation into either the peptide substrate or 
myosin IIB protein substrate (35).  We compared PF-TRPM7 and fully phosphorylated 
TRPM7-KD.  We reasoned that if autophosphorylation regulates TRPM7-KD activity, 
fully phosphorylated TRPM7-KD will initially phosphorylate its substrates more rapidly 
than the PF-TRPM7.  The comparison between the ability of fully phosphorylated TRPM7-
KD and PF-TRPM7 to phosphorylate the peptide substrate (figure 2.2B) demonstrated that 
autophosphorylation is essential to activate TRPM7-KD as PF-TRPM7 exhibits a lower 
initial rate of peptide phosphorylation than the fully phosphorylated TRPM7-KD.   
 
Characterization of the mechanism of TRPM7 autophosphorylation  
As previously established, the early autophosphorylation of PF-TRPM7 is 
sufficient for its full autoactivation.  To determine the effect of PF-TRPM7 concentration 
on its autophosphorylation, we examined how the rate of autophosphorylation varied with 
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the TRPM7 concentration.  Using a rapid quench flow kinetic assay, we were able to 
quantify the initial rate of 32P incorporation into PF-TRPM7 at different concentrations and 
determine the relationship between the rate of autophosphorylation and TRPM7 
concentration.  Rapid quench-flow kinetic experiments were performed at 7 different 
concentrations of TRPM7 between 50–3200 nM (figure 2.4).  The observed rate constant 
k1 for the initial rate of autophosphorylation varied from 0.01 to 0.08 sec
-1 and plateaued 
above 800 nM PF-TRPM7.  
 
Pre-steady state kinetic analysis of TRPM7-KD  
Our previous rapid quench data showed that fully active TRPM7 exhibits a 
transient pre-steady-state "burst" of a phosphorylated substrate.  Therefore, we studied 
kinetic transients on the catalytic reaction pathway of TRPM7 in detail.  Experiments were 
performed on a Rapid Quench-Flow apparatus as described in Materials and Methods.  To 
observe a burst of product formation, the concentration of substrate must exceed that of the 
enzyme and must exceed the dissociation constant, such that the majority of the enzyme 
will be bound to the substrate before initiation of the catalytic reaction.  For experiments, 
final concentrations of 3 mM MgATP, 25 μM peptide, and 0.5-1 μM TRPM7 were used.  
Both peptide and MgATP were incubated together in syringe A before rapid mixing with 
an equal volume of TRPM7 from syringe B.  At varying times, the reaction was stopped 
by the addition of a quench solution (400 mM EDTA).  Figure 2.5A shows 8 time courses, 
for the formation of peptide~p, obtained at two different concentrations of TRPM7 (0.5, 1 
μM).  The progress curve for each time course exhibited an initial burst followed by a 
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slower linear phase.  Data were fitted to an equation describing a single exponential 
followed by a steady-state rate (equation. 2.1).  The formation of the burst occurred with a 
rate constant of k2 = 27 s
-1 followed by a slow product release from the enzyme with a rate 
constant of k3 = 1.9 s
-1.  The amplitude of the burst exhibited a proportional dependence on 
the enzyme concentration when the experiments were performed at two different enzyme 
concentrations, 0.5 and 1 μM, respectively.  The burst amplitude indicates the quantity of 
active enzyme that is present in the reaction mixture.  The observed burst amplitudes (α) 
for each curve fit represented approximately 80% of the total enzyme concentration ([E]t, 
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) 𝑡                 Equation 2.1 
 
Three early phosphorylations are sufficient to fully activate TRPM7 
To further understand the mechanism we simultaneously monitored 
autophosphorylation and substrate phosphorylation using a rapid quench kinetic assay.  
Data were fitted to the following model (where E is PF-TRPM7 and EA is phosphorylated 
TRPM7-KD, S is the peptide substrate and P is the phosphorylated peptide substrate) using 





Figure 2.6A shows the fitted data, PF-TRPM7 exhibits a lag phase in its ability to 
phosphorylate the peptide substrate, which corresponds to the incorporation of 3 
phosphates into PF-TRPM7 (closed circles represents mole phosphate per mole TRPM7 
and closed squares present phosphorylated peptide) and as shown in figure 2.6A, fully 
phosphorylated TRPM7 does not exhibit such a lag phase.  Interestingly, after ~40-50 
seconds of autophosphorylation, the rate of myosin (TRPM7-KD protein substrate) 
phosphorylation by PF-TRPM7 became similar to the rate of phosphorylation by fully 
phosphorylated TRPM7-KD (data not shown), suggesting that early three 
autophosphorylation sites are sufficient for its kinase activity towards myosin.  These three 
autophosphorylation sites have been further determined by mass spectrometry analysis 
(figure 2.6B-D).  To determine these early autophosphorylation sites purified PF-TRPM7 
was allowed to autophosphorylate in the presence of MgATP for 30 seconds.  The sample 
was reduced, alkylated, and digested with trypsin as described under ‘2.3 Materials and 
Method’.  The relative degree of phosphorylation of the TRPM7 sites based on peak area 
ratios of phosphorylated and non-phosphorylated peptides from TRPM7-KD after 0 or after 
30 seconds of autophosphorylation was compared and the results (which have been 
summarized in figure 2.6D), revealed three major sites after 30 seconds of 
autophosphorylation in recombinant human TRPM7-KD - Ser1492, Ser1511 and Ser1567.  
It should be noted that only trace phosphorylation was detected in PF-TRPM7. 
Previously, Matsushita et al. reported that Ser1511 and Ser1567 are the major sites of 
TRPM7 autophosphorylation (31).  Accordingly, we investigated the contribution of the 
three autophosphorylation sites to TRPM7 kinase activity by generating mutant constructs.  
42 
In order to confirm these phosphorylation sites are important for TRPM7 activity, we 
mutated Ser1492, Ser1511 and Ser1567 individually to alanine and tested whether mutation of 
these autophosphorylation sites abolishes kinase activity.  Mutation of Ser1492, Ser1511 or 
Ser1567 to alanine resulted in almost no autophosphorylation compared with wild-type 
TRPM7-KD (figure 2.7A).  We also assessed the ability of these mutants that were 
autophosphorylated for different times (0.5–45 minutes) to phosphorylate a TRPM7 
peptide substrate.  None of the mutants showed significant peptide phosphorylation, as 
compared to the wild-type enzyme or any enhancement of enzyme activity following 
incubation with MgATP (figure 2.7B).  Myosin IIB exhibited similar results to the peptide 
substrate (figure 2.7C).  In addition, we mutated Ser1492, Ser1511 and Ser1567 to aspartic acid 
to mimic phosphorylation and investigated the ability of these mutants to 
autophosphorylate or phosphorylate myosin IIB.  The aspartic acid mutants showed a 
similar autophosphorylation level to the wild type TRPM7-KD (figure 2.8A) but only one 
of them (S1567D) rescued myosin IIB phosphorylation (figure 2.8B). 
As described in Chapter 1, by LC-MS/MS, Clark et al. identified 46 residues 
autophosphorylated in WT-TRPM7 including Ser1511 and Ser1567 which were identified 
earlier by Matsushita et al (31, 34).  However, Clark et al. reported that mutation of these 
residues to alanine either individually or in combination had no effect on TRPM7 
autophosphorylation or activity towards myosin II.  Their results are consistent with neither 
those of Matsushita’s nor our studies.  Their HA-tagged TRPM7 kinase domain was 
obtained from HEK293 cells by immunoprecipitation and subjected to an in vitro kinase 
assay.  These experiments raise the possibility that TRPM7 can undergo extensive 
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autophosphorylation and function normally in spite of mutation of Ser1511and Ser1567 to 
alanine by unknown factors in the cells.  By taking advantage of a rapid quench kinetic 
assay using PF-TRPM7, we demonstrated that Ser1492, Ser1511 and Ser1567 residues are 
absolutely essential for TRPM7 activity.  Autophosphorylation on these residues are 
required for further autophosphorylation of TRPM7 implying that their phosphorylation is 
an important priming event that would control TRPM7 autophosphorylation and kinase 
activity. 
 
The three autophosphorylation sites regulate the association with myosin II B 
As previously described in Chapter 1.2., the protein kinase domain of TRPM7 
phosphorylates actin filament interacting proteins: myosin II.  Clark et al. demonstrated 
that TRPM7 associates with myosin II in a kinase-dependent manner by showing that a 
kinase dead mutant (TRPM7-D1775A) did not interact with myosin IIA heavy chain (36).  
Interaction with the actomyosin cytoskeleton suggests that TRPM7 kinase activity might 
regulate the stability of actomyosin filaments and affect cytoskeletal remodeling.  
Therefore, we investigated whether the three early autophosphorylation sites influence the 
association of TRPM7 with the actomyosin cytoskeleton in the cells.  Accordingly, we co-
precipitated Myc-TRPM7 complexes (WT and three alanine mutants) with anti-Myc 
antibodies and detected the presence of associated myosin IIB by western blotting.  As seen 
in figure 2.9, myosin IIB heavy chain was present in a complex with WT TRPM7, but not 
in a complex with the mutants.  These results indicate that the interaction between TRPM7 
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and myosin IIB is strictly kinase activity-dependent and further confirm that the three 
autophosphorylation residues are the main regulators of the kinase activity.   
 
The autophosphorylation on three serine residues induces a conformational change 
of the TRPM7 kinase domain  
As mentioned earlier, TRPM channels have diverse C-terminal domains but share 
a common coiled-coil domain located at the C-terminus of the transmembrane domain.  
When recombinant proteins containing putative coiled-coils from TRPM channels are 
expressed by themselves, the coiled-coil domains are able to self-assemble into tetramers, 
as observed using biophysical techniques.  The deletion or point mutated coiled-coil 
domain was shown to result in a non-functional channel by abolishing multimeric channel 
assembly, suggesting that the tetramerized coiled coil is important for functional TRPM 
channels.  Moreover, recent X-ray crystallography of the TRPM7 coiled-coil domain 
(residues 1230-1282) demonstrated that TRPM7 coiled-coils were capable of forming 
tetrameric antiparallel structure (22).  The structure of the short TRPM7 alpha-kinase 
domain (residues 1548-1863) expressed in E.coli, determined by X-ray crystallography, 
revealed that TRPM7 alpha-kinase assemble into a dimer through the interaction of the N-
terminal alpha-helix of one subunit with the second subunit (33).  Taken together based on 
previous structural studies, there would be two kinase dimers in a tetrameric TRPM7 
channel.  The successful preparation of a phosphate-free form of the kinase domain of 
TRPM7 allowed us to determine the oligomerization state of this domain in both its non-
phosphorylated and fully phosphorylated form.  Using dynamic light scattering we found 
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that a phosphate-free form of TRPM7 exists as a tetramer in solution (figure 2.2 and 2.10).  
This observation increased the possibility that the TRPM7 oligomerization state can be 
influenced by autophosphorylation.  Therefore, we also performed dynamic light scattering 
on fully phosphorylated TRPM7-KD and autophosphorylated TRPM7-KD (30 seconds) in 
order to compare with tetrameric inactive TRPM7-KD.  The molar mass distribution, as a 
function of elution volume, is shown for each sample in figure 2.10.  The molecular mass 
of fully phosphorylated TRPM7-KD and autophosphorylated TRPM7-KD (30 seconds) is 
estimated to be 150 kDa in solution.  This is about twice the sequence derived mass of ~72 
kDa, which suggests that both fully phosphorylated and 30 second-autophosphorylated 
TRPM7-KD exist in a dimeric state.  These data support the notion that early 
autophosphorylation on three serine residues causes a conformational change to promote a 
tetramer to dimer transition of the kinase domain leading to an active enzyme.  As expected, 
alanine mutants which do not have an ability to be autophosphorylate and harbor kinase 
activity could not form a dimer (data not shown) and remained a tetramer.  Our data provide 
evidence that the active TRPM7 kinase domain is dimeric under physiological conditions.  
As a result, our findings propose a schematic model for the regulation of TRPM7 
conformational change as seen in figure (figure 2.11).  In the inactive state, the TRPM7 
kinase domain is tetrameric.  Activation of the kinase domain by autophosphorylation 
results in the structural transition of the kinase from the tetramer to dimer, potentially 




We provide evidence that three early autophosphorylation sites of TRPM7 (Ser1492, 
Ser1511 and Ser1567) regulate its autoactivity and its interaction with myosin II using a range 
of biochemical experimental techniques.  The evidence includes i) a concentration-
dependent autophosphorylation mechanism, ii) in vitro rapid quench kinetic analysis and 
MS/MS demonstrating that TRPM7 requires the early three phosphates to activate the 
kinase domain towards downstream substrates, iii) biochemical analyses of the TRPM7 
complex showing that TRPM7 associates with myosin II in a kinase dependent manner in 
cells and iv) dynamic light scattering analysis revealing that early autophosphorylation 




Figure 2.1. SDS-PAGE analysis of purified TRPM7-KD (1403-1864). 
A, In vitro treatment of purified TRPM7-KD with lambda phosphatase.  B, Purified PF-
TRPM7 kinase domain which was co-expressed with lambda phosphatase in E.coli.  
Proteins were expressed in E.coli (Rossita Gami 2 cells), purified and analyzed by 10% 
SDS-PAGE in tris-glycine running buffer using BenchMark Protein Ladder (Invitrogen), 
and stained with coomassie blue.  C, Autophosphorylation of PF-TRPM7. PF-TRPM7 (800 
nM) was allowed to autophosphorylate in the presence of 11 μM MgCl2.  At the indicated 
times, the reaction quenched with hot SDS-PAGE sample loading buffer.  The samples 
were then analyzed as described under ‘2.3. Materials and Methods’.  (upper) Coomassie-




Figure 2.2. Dynamic light scattering analysis of phosphate-free TRPM7 kinase 
domain. 
Fractionation of 3.6 µM phosphate-free TRPM7 kinase domain using size exclusion 
chromatography followed by quasi-elastic light scattering (QELS) analysis shows that 
phosphate-free TRPM7 self-association causes tetramerization.  The chromatographic 
conditions are given in the ‘2.3. Materials and Methods’.  The patterns represent the relative 
concentrations determined by measurement of the refractive index differences, the molar 





Figure 2.3. Autoactivity of TRPM7-KD towards peptide substrate.  
A, Activity of PF-TRPM7 pre-phosphorylated for designated time against peptide 
substrate. The incorporation of phosphate into 12.5 µM peptide substrate by PF-TRPM7 
pre-phosphorylated for different time points (0.5-100 min) monitored by general kinase 
assay using p81 paper.  B, Rapid quench flow kinetics experiment compares the ability of 
PF-TRPM7 and fully phosphorylated TRPM7-KD to phosphorylate 12.5 µM peptide 
substrate.  Closed squares represent the activity of 800 nM of fully phosphorylated 
TRPM7-KD towards its peptide substrate in the presence of a saturating ATP 
concentration.  Closed circles represent activity of 800 nM PF-TRPM7 towards its peptide 




Figure 2.4. Effect of different TRPM7 concentrations on its autophosphorylation. 
It was studied by investigating the concentration dependence of TRPM7-KD 
autophosphorylation rate constant.  Plotted is the observed rate constant (sec-1) for 
autophosphorylation versus TRPM7-KD concentration (nM).  The incorporation of 
phosphate into different concentrations of PF-TRPM7 was monitored by rapid quenched 
flow kinetics.  The lines are the best fits of each data set to the following equation kobs = 
kmax +[E]/[E]+´ dK  where kobs is the observed rate constant, kmax is the maximum observed 






Figure 2.5. Product release as the rate limiting step in the kinetic mechanism of 
TRPM7 kinase domain.  
A, Rapid mixing of MgATP with TRPM7-KD•Peptide substrate.  Rapid quench-flow 
experiments were conducted at 27 °C and pH 7.5 in assay buffer (25 mM HEPES, 50 mM 
KCl, 2 mM DTT, 0.1 mM EDTA, and 0.1 mM EGTA) containing 10 mM MgCl2. [γ-
32P] 
ATP (100-1000 cpm/pmol) and peptide substrate mixture were loaded into sample loop A, 
while TRPM7-KD were loaded into sample loop B.  Final concentrations were 1 mM 
MgATP2-, 25 µM peptide substrate, and 0.5 (circle), 1 µM (square) TRPM7-KD.  At set 
times, reactions were quenched by the addition of quenching buffer (20 mM HEPES pH 
7.4, 200 mM KCl, 0.1% bovine serum albumin, 50 mM EDTA, 1 mM EGTA) and product 
formation (EAP + P) was quantified as described in ‘2.3 Materials and Methods’.  The 
lines through the data correspond to the best fit to equation 2.1 according to an average k2 
of 26.5 s-1 and k3 of 1.84 s-1.  B, Reaction scheme.  
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Figure 2.6. Three early autophosphorylation events are required for TRPM7 
autoactivation.  
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Figure 2.6 continued.  
A, Fitted rapid quench kinetic data showed that PF-TRPM7 became active towards 
substrates after incorporation of the first 2-3 phosphates which was confirmed by lag phase 
of peptide phosphorylation until TRPM7 gets ~3 phosphates.  (Closed circle curve 
represents mole phosphate per mole TRPM7 and closed square curve presents 
phosphorylated peptide).  Data were fitted using Kintek explorer software to the following 
model (E=EA, EA+S=EAS, EAS=EA+P).  B-D, Mass spectrometric analysis of 
autophosphorylation sites in TRPM7-KD. Base peak ion chromatogram of B, PF-TRPM7 
and C, after 30 seconds of autophosphorylation.  D, Relative degree of phosphorylation of 
TRPM7 sites based on peak area ratios of phosphorylated and non-phosphorylated peptides 
from TRPM7 after 0 or after 30 seconds of autophosphorylation.  Peak area ratio = peak 
area for phosphorylated peptide / peak area for non-phosphorylated peptide.  The ratios 







Figure 2.7. The effect of Alanine mutation of the early phosphorylation sites on 
TRPM7-KD autophosphorylation and kinase activity against either peptide and or 
protein substrate (myosin IIB).  
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Figure 2.7 continued.  
A, Autophosphorylation of wild type PF-TRPM7 and mutant TRPM7 in which Ser1492, 
Ser1511, and Ser1567 were changed to alanine residues.  Either WT PF-TRPM7 or each 
mutant was incubated with [32P] MgATP for 30 min and 60 min.  Samples were separated 
by SDS-PAGE (upper) and analyzed by autoradiography (lower).  B, Activity of PF-
TRPM7 and each alanine mutant that were pre-autophosphorylated for different time points 
against 12.5 µM peptide substrate and saturating concentration of ATP.  C, Kinase activity 
of PF-TRPM7 and each alanine mutant against myosin IIB.  Either wild type PF-TRPM7 
or each alanine mutant was incubated with [32P] MgATP and myosin IIB for 30 min.  





Figure 2.8. The effect of aspartate mutation of the early phosphorylation sites on 
TRPM7-KD (A) autophosphorylation and (B) ability to phosphorylate its protein 
substrate myosin IIb substrate.  
A, Autophosphorylation of wild type PF-TRPM7 and three mutants in which Ser1492, 
Ser1511, and Ser1567 were changed to aspartic acid residues.  Either wild type PF-TRPM7 
or mutant was incubated with [32P] MgATP for 60 min.  Samples were separated by SDS-
PAGE (upper) and analyzed by autoradiography (lower).  B, Either wild type PF-TRPM7 
or each aspartate mutant was incubated with [32P] MgATP and myosin IIB for 30 min.  







Figure 2.9. The effect of alanine mutation of the early phosphorylation sites on 
TRPM7 –myosin interaction in HEK293 cells.  
Full length of Myc-FLAG tagged TRPM7 WT and Alanine mutants were transfected into 
HEK293 cells and immunoprecipitated with anti-Myc antibody-containing beads 
according to the protocol described in ‘2.3 Materials and Methods’ and associating myosin 





Figure 2.10. Dynamic light scattering analysis: Effect of autophosphorylation on the 
self-association of TRPM7 kinase domain.  
Fractionations of inactive TRPM7 (PF-TRPM7) and active TRPM7 (Fully phosphorylated 
TRPM7-KD and 30 sec-autophosphorylated TRPM7-KD) show that early TRPM7-KD 





Figure 2.11. Schematic model: Activation of TPRM7 catalytic domain. 
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Chapter 3: Suppression of Breast Cancer Cell Migration by Novel 
Inhibitors Targeting TRPM7 Kinase Activity‡ 
 
3.1 ABSTRACT 
TRPM7 (transient receptor potential melastatin 7) is a non-selective cation channel 
that is permeable to both Ca2+and Mg2+ and is implicated in cell adhesion and magnesium 
homoeostasis.  The TRPM7 channel possesses a protein kinase domain at the C-terminus 
whose activity is linked to the control of actomyosin contractility.  TRPM7 mediates 
proliferation, adhesion and migration of breast cancer cells and recently has been reported 
to promote breast tumor cell metastasis.  The lack of cell-permeable pharmacological 
inhibitors of the kinase domain represents a barrier to fully understanding its kinase 
function.  Herein, we describe the discovery of the first group of small molecule 
compounds that target TRPM7 kinase activity and characterize their mechanism of 
inhibition in vitro and in cells.  These compounds were shown to decrease the binding of 
myosin IIB to TRPM7 in cells transfected with pCMV6-TRPM7.  Interestingly, two of the 
inhibitors significantly inhibited MDA-MB-231 breast cancer cell migration, which is 
reportedly regulated by TRPM7 kinase activity. 
 
3.2 INTRODUCTION 
                                                 
‡ Contributions to the work described in this chapter: Dr. Tamer S. Kaoud (Performed biochemical screening 
assays); Dr. Shreya Mitra (Analyzed breast cancer cell migration assay); Anna Tseng (Helped biochemical 
assays).  
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As described above, TRPM7 (transient receptor potential melastatin 7) is a non-
selective cation channel that is permeable to both Ca2+and Mg2+ as well as metal ions and 
is fused to a protein kinase domain at the C-terminus whose activity is linked to the control 
of actomyosin contractility.  The ion-conducting properties of TRPM7 can be modulated 
by different stimuli, resulting in a variety of cellular responses.  The expression of the 
TRPM7 channel is widespread and is found in cancer cells such as retinoblastoma, neck 
and head, gastric and breast(39, 41, 42).  Whether TRPM7 activity contributes to cancer 
progression has not been delineated in detail.  Central to tumor metastasis is the capacity 
of tumor cells to adhere to cells and tissue that differ from the original site.  Metastasis 
occurs through a complicated multistep process including tumor cell dissemination, cell 
invasion, entry into the bloodstream and outgrowth of secondary tumors in distant 
organs(45).  The continuous Ca2+-mediated regulation of actomyosin contractility, as well 
as cytoskeletal dynamics is required for each step of metastasis.  Therefore, as a regulator 
of actomyosin contractility, cell motility and proliferation, TRPM7 was suggested to be a 
potential target for the pharmacological treatment of cancers. 
Earlier studies in human gastric cancer cells showed that blockade of TRPM7 
channels or knockdown of TRPM7 expression by siRNA inhibited cancer cell growth and 
induced apoptosis, implying the potential function of TRPM7 in the growth and 
proliferation of cancer cells.  In breast cancer cells, previous studies have shown that 
calcium is involved in the control of proliferation and apoptosis.  It has been reported that 
there is a clinically relevant link between TRPM7 levels and metastatic disease in breast 
cancer patients (44).  The TRPM7 channel was overexpressed in grade III breast cancer 
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samples and associated with tumor size.  In earlier work, Middelbeek et al. showed that 
knocking down TRPM7 expression by siRNA transfection in invasive human breast cancer 
cells impaired their ability to migrate in vitro and their metastatic potential in a mouse 
xenograft model of human breast cancer (44).  Moreover, a recent study from Guilbert et al. 
suggested that TRPM7 is involved in estrogen receptor-negative metastatic breast cancer 
cells migration through its kinase domain by showing that overexpression of the kinase 
domain-truncated TRPM7 decreased the number of adherent cells and strongly inhibited 
cell migration while the overexpression of the WT TRPM7 significantly increase it (43).  
Taken together, these findings suggest that TRPM7 is a key player in modulating 
adhesion and migration of MDA-MB-231 cells and suggest that TRPM7 could be a 
potential therapeutic target for limiting the metastatic potential of cancer cells.  However, 
molecular mechanisms underlying the contribution of TRPM7 to cancer cell proliferation 
and migration is still not fully elucidated.  In addition, the lack of cell-permeable 
pharmacological inhibitors of the TRPM7 kinase domain represents a barrier to fully 
understand the kinase domain’s function.   
In this study, we discovered small molecule inhibitors that target TRPM7 kinase 
activity by screening a compound collection from NCI and characterized their mechanism 
of inhibition.  The compounds inhibited the association between TRPM7 and myosin in 
HEK293 cells.  Furthermore, some compounds were shown to significantly suppress 
MDA-MB-231 breast cancer cell migration.  Our results support a previous study 
suggesting that TRPM7 plays a role in breast cancer cell migration through its kinase 
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domain.  These small molecule compounds represent the first group of inhibitors to target 
the kinase activity of TRPM7, resulting in the inhibition of breast cancer cell migration.  
 
3.3 MATERIALS AND METHODS 
Biochemical Screening of NCI natural products set and challenge set  
Four 96-well plates were provided by NCI and used for the kinase screening.  
Phosphorylation of 10 µM of TRPM7 peptide substrate (acetyl-RKKYRIVWKSIFRRFL-
amide) were tested using 25 nM of fully phosphorylated TRPM7 in kinase assay buffer (25 
mM HEPES (pH 7.6), 10 mM MgCl2, 50 mM KCl, 2 mM DTT, 0.1 mM EDTA, 0.1 mM 
EGTA, 0.03 % Brij-35, 5-10% DMSO and 10 μg/ml BSA) in the presence of 10 µM of 
each compound.  Each reaction mixture was incubated in a volume of 90 µL per well in 
96-well plate at room temperature for 30 minutes.  The reactions were initiated by the 
addition of 10 µL [γ-32P] ATP, adjusting the ATP concentration to 200 μM (100-1000 
c.p.m. pmol-1).  The reaction was incubated at room temperature for 10 minutes and then 
quenched by transferring 80 μL of reaction mixture to each well of a P81 96-well filter 
plate (Unifilter, Whatman) containing 200 μL of 0.1 M phosphoric acid solution.  The P81 
filter plate was washed 7-8 times with 200-300 mL of 0.1 M phosphoric acid solution and 
one time with pure acetone, followed by the addition of 20 mL of scintillation cocktail.  A 
MicroBeta TriLux liquid scintillation counter (PerkinElmer) was used for screening. 
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In Vitro Kinase Inhibition Assay  
Kinase inhibition assays were conducted at 30 °C in assay buffer (25 mM HEPES 
buffer-pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT and 10 μg mL-1 
BSA), containing 300 μM [γ-32P] ATP (100-1000 c.p.m. pmol-1), 11 mM MgCl2 and 
different concentrations of each compound in a final total volume of 70 µL, containing 5-
10 % DMSO and 0.03% Brij-35 surfactant.   
For TRPM7 assays, 25 nM of fully phosphorylated TRPM7 were assayed with 10 
µM of TRPM7 peptide substrate (acetyl-RKKYRIVWKSIFRRFL-amide).  For eEF2K, 2 
nM eEF2K were assayed with 50 µM eEF2K peptide substrate (acetyl-
RKKYKFNEDTERRRFL-amide) (142).  Activity was assessed at different compound 
concentrations by the measurement of initial rates, where the total product formation 
represented less than 10% of the initial substrate concentrations.  Every reaction was 
initiated by the addition of ATP.  At set time points (0.5, 1, 1.5, 2, 4 min), 10 μl aliquots 
were taken from every reaction and spotted onto 2×2 cm2 squares of P81 cellulose paper; 
the papers were washed 3 times for 15 minutes each in 50 mM phosphoric acid (H3PO4), 
followed by a pure acetone wash, then dried.  The amount of labeled protein was 
determined by counting the associated c.p.m. on a Packard 1500 scintillation counter at a 
sigma value of 2. 
Cell culture  
HEK293T cells were maintained in DMEM (Invitrogen) supplemented with 2 mM 
L-glutamine (Invitrogen), 10% (v/v) FBS-US grade (Invitrogen), 100 g mL-1 streptomycin 
(Sigma) and 100 U mL-1 penicillin (Sigma).  Cells were cultured at 37 °C in a humidified 
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5% CO2 incubator.  For myosin co-immunoprecipitation experiments, cells were seeded in 
a 12-well plate at 400,000 cells per well and the pCMV6-Entry vector containing DNA 
encoding for full length TRPM7 (Myc-DDK-tagged)-Human transient receptor potential 
cation channel, subfamily M, member 7 (Origene) was transfected into HEK293T cells by 
lipofectamine 2000 (Invitrogen, California, USA) according to the manufacturer’s 
protocol.  After 48 hours of transfection, cells were incubated with different concentrations 
of the compounds for additional 16 hours in serum free media except the compound 5 
which was incubated for 3 hours and finally, cells were treated with bradykinin (10-50 nM) 
for 30 minutes in full media.  For cell migration experiment, MDA-MB-231 cells were 
maintained in RPMI media (Cellgro, Mediatech) with 5% (v/v) FBS (Gemini Bio-
Products) 100 U mL-1 penicillin (Sigma), and 100 g mL-1 streptomycin (Sigma).  Cells 
were pre-incubated with 10 µM of each tested compound for overnight, prior to the 
migration assays.  The compounds were maintained in the culture media for the duration 
of the experiment.   
 
Data Analysis  
Steady-state kinetic experiments - Reactions were carried out as mentioned in the 
kinase activity assay except in the kinetic mechanism study, where we varied 
concentrations of substrate (ATP) and compound 2.  Initial rates were determined by linear 
least squares fitting to plots of product against time.  Reciprocal plots of 1/v against 1/s 
were checked for linearity, before the data were fitted to equation 3.1 using a non-linear 
least squares approach, assuming equal variance for velocities, using the program 
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Kaleidagraph 3.5 (Synergy software).  Values for kinetic constants were then obtained 
using the program Sigma plot by fitting the kinetic data to the relevant over-all equation.  
Data conforming to linear competitive inhibition were fitted to equation 3.2; data 
conforming to hyperbolic mixed inhibition were fitted to equation 3.3.  Dose-response 







After washing the cells with PBS (Invitrogen), the lysates were prepared in lysis 
buffer containing 50 mM Tris pH 7.5, 300 mM NaCl, 0.5 mM NaCl, 0.5 mM DTT, 1.5 
mM MgCl2, 0.2 mM EDTA, 1% Triton X-100 supplemented with protease and 
phosphatase inhibitors and then cleared by centrifugation.  The protein concentration was 
measured by Bradford analysis (Bio-Rad).  For immunoprecipitation of exogenously 
expressed TRPM7, Myc-Tag (9B11) Mouse mAb (Sepharose Bead Conjugate) (Cell 
Signaling Technology) were added to the lysate, the samples were incubated at 4 °C 
overnight.  Subsequently, the beads were washed three times with lysis buffer, protein 
complexes were solubilized in Laemmli sample buffer and separated by SDS-PAGE.  
Proteins were fractionated on a 10% SDS polyacrylamide gel (Bio-Rad) and transferred to 
Hybond-P PVDF Membrane (GE Healthcare).  Primary antibodies were incubated 
overnight at 4 ºC using 1:1000 anti-myosin IIB rabbit polyclonal antibodies (Cell Signaling 
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Technology); anti-rabbit (Bio-Rad) horseradish peroxidase-conjugated secondary 
antibodies and ECL Plus™ Western Blotting Reagents (GE Healthcare) were employed to 
develop the blots. 
 
Cell migration  
A modified Boyden chamber (Millipore) was used to measure cell migration.  
About 50,000 cells, rinsed and resuspended in serum free RMPI, were added into the upper 
chamber of trans-well separated by inserts with 8 μm pores.  A chemotactic gradient was 
created by adding HBSS (Hank's Buffered Salt Solution) medium containing 1% (v/v) FBS 
to the lower chamber.  Cells were allowed to migrate for 6 hours.  After fixing the migrated 
cells with 4% paraformaldehyde, they were stained with 0.5% (w/v) crystal violet, and 
quantified by counting four randomly chosen fields (at an objective of 10 ×).  
 
3.4 RESULTS AND DISCUSSION 
Our biochemical screening identified five compounds (Table 3.1) exhibiting 
considerable inhibition of TRPM7 kinase activity when assayed at a concentration of 10 
µM.   
 
Prioritizing hits and potential mechanisms of inhibition by the identified inhibitors  
To prioritize the 5 hits identified in the biochemical screening we performed dose-
response curves, examining the ability of the compounds to inhibit the phosphorylation of 
a peptide substrate by the TRPM7 kinase domain in an in vitro kinase assay (table 3.1 and 
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figure 3.1).  To further understand the mechanism of TRPM7 kinase domain inhibition by 
these compounds we tested the ability of these compounds to suppress TRPM7 
autophosphorylation.  Three compounds (1-3) were able to inhibit TRPM7 kinase domain 
autophosphorylation, while the other two compounds did not affect autophosphorylation 
(table 3.1).   
We determined kobs over a range of Mg-ATP concentrations at different fixed 
concentrations of compound 1, in the presence of a saturating concentration of peptide-
substrate.  The double reciprocal plot derived from this study (figure 3.2) is consistent with 
a mechanism of competitive inhibition (figure 3.2, where Ki ~ 0.7±0.04 µM).  According 
to this model, compound 1 binds TRPM7 and alters its affinity for ATP without affecting 
kcat.   
 
Selectivity of the compounds  
To profile the selectivity of the five compounds towards the TRPM7 kinase domain, 
the IC50 of each compound was determined against another atypical alpha kinase eEF2K 
that has been reported to be structurally similar to the TRPM7 kinase domain(143).  Dose 
response inhibition assays against eEF-2K were performed using 2 nM eEF-2K, 50 μM [γ-
32P] ATP, 30 μM Pep-S (acetyl-RKKYKFNEDTERRRFL-amide), and various 
concentrations of each compound.  Most notably, compound 1 exhibits a 700-fold 
selectivity for TRPM7 over eEF2K.  The selectivity profile of these compounds strongly 
demonstrates the ability of the screening protocol to identify molecules that target TRPM7 
kinase domain with selectivity. 
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Cellular Activity  
It has been reported that myosin binding to TRPM7 is triggered by kinase domain 
autophosphorylation.  Unlike TRPM7–WT, TRPM7-D1775A (Kinase dead TRPM7) does 
not interact with myosin IIA heavy chain (36).  The ability of the five compounds to inhibit 
the TRPM7 interaction with myosin IIB were examined in HEK293 cells following 
stimulation by bradykinin (36) and visualized through western blot analysis (figure 3.3).  
Compounds 1, 2 and 5 showed inhibition of the TRPM7-myosin interaction in HEK293 
cells, with compound 1 exhibiting ~75% inhibition at a concentration of 50 µM.  It should 
be noted that the protein substrates concentration in the cell is significantly lower than 
MgATP.  Thus, a non-ATP competitive inhibitor does not have to be as potent as an-ATP 
competitive inhibitor to achieve an acceptable effective dose-50 (ED50) in cells.  For 
example, in figure 3.3, compare the degree of inhibition of 50 µM of compound 1 (an ATP-
competitive inhibitor of TRPM7 kinase domain whose IC50 is 0.5 µM) with that of 
compound 5 (a non ATP-competitive inhibitor whose IC50 is 3.5 µM).   
 
TRPM7 kinase domain inhibitors impedes migration of breast cancer cells  
The invasion-metastatic cascade involves a series of events whereby tumor cells 
leave the primary tumor, intravasate into the circulation, extravasate at distant tissues, and 
establish micrometastases that may grow into macroscopic secondary tumors (144).  Cell 
migration is an early requirement for tumor metastasis, so inhibition of cell migration 
provides a potential strategy to inhibit metastasis (145).  A recent study has reported the 
importance of TRPM7 for breast tumor cell metastasis as TRPM7 knockdown inhibits the 
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migration of invasive human triple negative breast cancer cells (MDA-MB-231)(44), 
although the effect was significant but the absence of inhibitors that specifically inhibit 
TRPM7 kinase domain acted as a barrier to determine if this effect on metastasis returns to 
the channel or the kinase domain.  Interestingly, Guilbert et al. has finally reported that 
TRPM7 is involved in oestrogen receptor-negative metastatic breast cancer cells migration 
through its kinase domain (43).  We examined whether any of the identified compounds 
inhibited chemotactic cell migration of a highly metastatic human breast cancer cell line 
namely MDA-MB-231 in a trans-well assay.  MDA-MB-231 cells were treated with 
DMSO, or compounds 1-5 (10 µM) (figure 3.4) overnight.  Cell viability was monitored 
during the migration assay and found to be unaffected by the addition of the compounds.  
Untreated MDA-MB-231 cells showed robust migration in response to serum, while cells 
treated with 10 µM of compounds 1 and 5 exhibited approximately 80% inhibition of 
migration (figure 3.4).   
 
3.5 CONCLUSION  
The NCI natural products and challenge sets were screened against the kinase 
activity of the TRPM7 kinase domain.  A total of 5 small molecules were identified as 
inhibitors of the TRPM7 kinase domain.  Compound 1 showed marked selectivity for 
TRPM7 over eEF2K and showed 80% inhibition of MDA-MB-231 breast cancer cell 
migration at a 10 µM concentration.  The inhibitors described here represent a starting 
point for the development of selective small molecules capable of compromising the kinase 


























Table 3.1 continued, next page. 
4.5 Yes 27 
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3.5 No 41.6 
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Figure 3.1. The effect of compounds 1-5 on the ability of TRPM7 kinase domain to 
phosphorylate its peptide substrate.  
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Figure 3.2. Mechanism of TRPM7 inhibition by compound 1   
Double reciprocal plot of 01 V  vs 1/[ATP] at varied fixed concentrations of compound 1 
(0-11.25 µM) and 10 µM peptide substrate.  Initial velocities were measured using various 
(50–800 µM) concentrations of ATP.  The data were fitted to a model of linear competitive 
inhibition according to equation 3.2, where app
catk  = 0.4 ± 0.02 s
-1, appmK  = 253 ± 24 µM, 
app




Figure 3.3. Examining the ability of the tested compounds to modulate TRPM7-
myosin interactions in HEK293 cells.   
The effect of compounds 1, 2 and 5 on TRPM7 interaction with myosin IIB was 
investigated by TRPM7 immunoprecipitation using anti-Myc beads and associating 






Figure 3.4. TRPM7 kinase domain inhibitors inhibit MDA-MB-231 breast cancer cell 
migration. 
Representative images of migrated cells on the underside of a trans-well membrane stained 
with crystal violet dye.  10 µM of compounds 1 and 5 significantly reduces the number of 
cells that travel through the trans-well pores to successfully reach the underside of the 
trans-well membrane (migrated cells) in comparison to the untreated cells.  This 
experiment has been independently repeated three times, each one as a triplicate. 
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Chapter 4: Identification of Small Molecule Inhibitors for PERK 
through Luminescence High Throughput Screening and 




An adaptive stress response mechanism, termed the unfolded protein response 
(UPR), is activated in a variety of tumor types to cope with ER stress and maintain protein 
homeostasis.  PERK (PKR-like endoplasmic reticulum kinase) is a key components of the 
UPR.  PERK is a Ser/Thr protein kinase whose active homodimer phosphorylates 
eukaryotic initiation factor 2α (eIF2α), thereby inhibiting protein translation globally and 
reducing the load of newly synthesized proteins entering the ER.   Many studies reported 
that the UPR is activated in a variety of tumor types.  Previous studies demonstrated that 
cells with a compromised PERK signaling pathway are sensitive to hypoxic stress in vitro 
and form tumors that grow more slowly in vivo.  Together, these data suggest a substantial 
role for PERK and the UPR in tumor cell survival and adaptation to stress.  Thus, selective 
inhibitors of PERK activity may be useful therapeutic candidates for the treatment of 
cancer.  In this study, we discovered potent inhibitors of PERK by high throughput 
screening of small molecule libraries.  Using an HTS approach a number of lead 
                                                 
†† Contributions to the work described in this chapter: Dr. Eun Jeong Cho and Dr. Ashwini K. Devkota 
(Helped high throughput screening at TI3D); Dr. Ramakrishna Edupuganti (Synthesized PERK specific 
inhibitor, GSK2606414); Dr. Tamer S. Kaoud, Dr. Clint D.J. Tavares, and Dr. Qiantao Wang (Helped design 
experiments, and contributed reagents, materials and analysis tool).  
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compounds were identified with demonstrated ability to inhibit PERK kinase activity in 
vitro.  Several potent PERK inhibitors were further tested in a cell-based assay to evaluate 
modulation of the PERK signaling pathway. 
 
4.2 INTRODUCTION 
Protein folding is necessary for newly synthesized proteins to attain a correct 
conformation before exiting from the ER.  Accumulation of unfolded or misfolded proteins 
in the ER occurs when the cell is subject to stress caused by various pathological 
disturbances.  Under such stress the cell will initiate a protective mechanism named the 
unfolded protein response (UPR) that is specifically designed to restore homeostasis and 
normal ER function (56, 57).  This stress survival mechanism attenuates overall protein 
translation; however, it enhances the translation of a small number of stress survival 
proteins such as HIF-1α, c-Myc and VEGF (77-80).  During tumorgenesis, cancer cells need 
to tolerate cellular stresses such as oxidative stress, nutrient deprivation or disruption of 
ER redox status.  In order to adapt to and overcome the stress, tumor cells remodel 
transcriptional and translational programs by activating pro-survival signaling pathways.  
The unfolded stress response (UPR) is responsible for detecting ER stress and reacting to 
increased levels of unfolded or misfolded proteins in the ER.  Tumor cells, which are 
frequently subjected to increased levels of unfolded proteins, hypoxia and glucose 
deprivation may be dependent on the UPR for survival (81).  
The UPR is initiated by several proteins such as IRE1, ATF6 and PERK.  It has 
long been recognized that the majority of solid tumors contain areas of hypoxia because of 
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an abnormal tumor vasculature (115).  To overcome the effects of hypoxia, tumors take 
advantage of the UPR by phosphorylating eIF2α through activation of PERK as an adaptive 
mechanism.  PERK is a serine/threonine kinase that is activated by a cell’s UPR, which 
detects the presence of unfolded proteins in the ER.  PERK has been shown to be critical 
to tumor cell adaptation and angiogenesis in response to hypoxic stress (80, 118).  Using 
PERK-/-MEFs, it was observed that failure of tumor cells to activate the UPR results in 
increased apoptosis, reduced cell survival and inhibition of tumor growth (80, 118).  
Therefore, PERK is a potential candidate protein for targeting tumor stress.  
Accordingly, PERK became an active target for drug design in academia and the 
pharmaceutical industry.  The goal of this study was to identify inhibitors using high 
throughput screening that exhibit selective PERK inhibition.  Despite PERK being 
identified as a therapeutic target, no specific small molecule inhibitor that targeted PERK 
had been reported when we initiated our research.  In a recent study, Axten et al. reported 
a selective ‘first in class’ inhibitor of PERK (GSK2606414) through screening and lead 
optimization using the human PERK crystal structure (scheme 4.1) (124).  The compound 
GSK2606414 has an IC50 of 0.4 nM in vitro which was measured using the GST–PERK 
kinase domain and His-tagged full-length recombinant human eIF2α substrate.  In addition, 
Axten et al. demonstrated that this compound inhibits PERK activation in a cellular assay 
(IC50=30 nM) and inhibits the growth of a human tumor xenograft in mice.   
Small molecule inhibitors are generally discovered in a high throughput assay 
system where a large number of compounds are screened against a target enzyme in an 
automated fashion using a suitable assay.  High throughput Screening (HTS) is an approach 
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in drug discovery that has gained widespread popularity.  A radiation-based 32P assay is a 
common protein kinase assay format.  However, radiation-based screening produces 
numerous challenges for HTS, such as radioactive contamination of the work environment 
and safety issues, so it is not suitable for HTS.  In this study, we optimized a nonradioactive 
screening method based on luminescence generated by firefly luciferase.  The kinase-Glo 
TM luminescent kinase assay (Promega, Madison, WI) determines relative ATP levels 
remaining in solution following a kinase reaction by luciferase-mediated luminescence.  
The intensity of the luminescence signal is inversely correlated to kinase activity.  Herein 
we report utilizing a luminescent kinase assay to determine PERK activity in an HTS 
application using a 384 well plate format.  After optimization of enzyme, substrate, and 
ATP concentrations, we screened small molecule libraries and identified several lead hits.  
The lead compounds were demonstrated to weakly inhibit PERK autophosphorylation and 












4.3 MATERIALS AND METHODS 
Reagents and equipment 
Competent cells used for amplification and expression were provided by Novagen 
(Gibbstown, NJ).  Yeast extract and tryptone were purchased from US biological 
(Swampscott, MA).  IPTG and DTT were obtained from USB (Cleveland, OH).  Most of 
the buffer components including HEPES, Trizma base (Tris), sodium chloride, potassium 
chloride, EDTA, EGTA, calcium chloride, magnesium chloride, Brij-35, Triton X-100, β-
mercaptoethanol, benzamidine hydrochloride, TPCK and PMSF were purchased from 
Sigma (St. Louis, MO).  Ni-NTA agarose was supplied by Qiagen (Santa Clarita, CA) 
while all other components used in the protein expression and purification was obtained 
from Fisher Scientific (Pittsburgh, PA).  Amersham Biosciences (Pittsburgh, PA) provided 
the FPLC system and the columns for purification.  P81 cellulose papers were obtained 
from Whatman (Piscataway, NJ).  ATP was purchased from Roche (Indianapolis, IN).  
Radiolabelled [-32P] ATP was obtained from Perkin Elmer (Waltham, MA).  ADP was 
from MP Biomedicals (Solon, OH). 
 
PERK Cloning 
The original expression empty vector (GVL2) was kindly provided by Dr. Yan 
Jessie Zhang (Department of Chemistry and Biochemistry, University of Texas at Austin).  
This expression vector was derived from pET28a vector (Novagen) containing N-terminal 
hexahistidine tag and GST tag followed by multiple cloning sites (MCS).  Ligation 
independent cloning (LIC) site was introduced into the MCS by one step PCR reaction 
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using pfuUltra polymerase (Stratagene).  The PCR was performed using the following 
primers:  a forward primer, 5'- GGT GGC TCT GGG TCA AGT AAA GGT GGA TAC 
GGA TCC-3'  and a reverse primer, 5'- GCC GGG TCC CTG AAA GAG GAC TTC AAG 
TGA GCT CGA TTT TGG AGG-3'. The linearized GVL2-3C/LIC vector was then treated 
for 1 hour at room temperature with T4 DNA polymerase (NEB) in NEB buffer 2 
containing 2.5mM dTTP and the reaction was stopped by heat inactivation at 75°C for 20 
minutes.  The human PERK truncated kinase domain (550-1116 a.a) (GenBank accession 
number: NM_004836.5) was amplified by PCR reaction using the forward primer (5’-CAG 
GGA CCC GGC TCA GGA ATG AGG CAA AGG AAG GAG TCT GAA-3’) and the 
reverse primer (5’-GAC CCA GAG CCA CC TTA TTT-3’).  The PCR amplification 
reaction mixture (50 l) contained 1X PfuUltra™ HF reaction buffer (Tris (pH 8.0) and 2 
mM Mg2+), 200 M of each dNTP, 0.2 M each of the forward and reverse primer, 10 ng 
of DNA template and 1U of PfuUltra™ HF polymerase.  The PCR cycle conditions 
included initial denaturation at 95 ˚C for 3 minutes, followed by 35 cycles of denaturation 
at 94 ˚C for 30 seconds, primer annealing at 57 ˚C for 1 minute and extension at 72 °C for 
5 minutes, with a final elongation step of 72 °C for 10 minutes.  The PCR product was gel 
purified and ligated into previously prepared linearized GVL2-3C/LIC vector.  The ligated 
product was transformed into the E. coli DH5 cells.  A single colony was isolated and 
amplified and the extracted plasmid DNA was verified for sequencing at the ICMB core 
facilities, UT-Austin, using an applied Biosystems automated DNA sequencer. 
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PERK Expression (550-1116) 
Recombinant human PERK was expressed in E. coli strain Rosetta-gamiTM 2 (DE3) 
(Novagen).  The strain was chosen to facilitate the expression of human PERK since it 
contains many rare codons (almost 9% of the total codons).  Rosetta-gamiTM 2 (DE3) 
carries the pRARE2 plasmid that provides tRNAs for seven rare codons.  The PERK kinase 
domain expression construct was transformed into Rosetta-gamiTM 2 (DE3) chemical 
competent cells.  A single isolated colony was used to inoculate 100 mL of LB media 
containing 50 µg/mL kanamycin, 34 µg/mL chloramphenicol and 10 µg/mL tetracycline 
and the culture was grown overnight at 37 °C with shaking at 250 rpm.  Next day the 
overnight culture was diluted 100 fold into 1000 mL 2xYT media containing same 
concentrations of antibiotics and were grown at 37 °C for 5-6 hours for OD600 to reach 0.6.  
Cultures were induced with 0.1 mM IPTG for 16 hours at 25 °C.  Then the cells were 
harvested by centrifugation (5000 rpm for 20 minutes at 4 ºC), flash frozen in liquid 
nitrogen and stored at -80 °C until lysis.    
 
PERK Purification (550-1116) 
Ni-NTA affinity chromatography 
 Aliquot of the frozen cell pellet from each liter of culture was resuspended in 50 
mL lysis buffer (50 mM Tris pH 8.0, 250 mM NaCl, 10 mM Imidazole, 0.1% β-
mercaptoethanol, 1 % triton X-100 (v/v), 1 mM benzamidine, 0.1 mM PMSF, 0.1 mM 
TPCK and 0.1 mg/mL lysozyme).  The suspension was sonicated for a total of 20 minutes 
at 5 second pulse with 5 second intervals in ice at 4 °C.  The lysate was centrifuged for 30 
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minutes at 16,000 rpm at 4 ºC.  The supernatant containing the protein fractions were 
incubated with Ni-NTA beads (Qiagen) for 1 hour at 4 ºC.  The beads were washed with 
100 mL wash buffer (50 mM Tris pH 8.0, 500 mM NaCl, 40 mM Imidazole, 0.1% β-
mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF and 0.1 mM TPCK).  The His6-GST-
3C-PERK protein was eluted with 20 mLs of elution buffer (50 mM Tris pH 8.0, 500 mM 
NaCl, 500 mM Imidazole, 0.1% β-mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF 
and 0.1 mM TPCK).  The concentration was estimated based on the absorbance at 280 nm 
(A280) in spectrophotometer using the extinction coefficient of 112370 cm
-1M-1 and path 
length of 1 cm. 
3C Protease cleavage 
 The His6-GST-3C-PERK protein eluted from Ni-NTA affinity chromatography 
was dialyzed in 4 L of 3C Cleavage buffer (25 mM HEPES, 200 mM NaCl, 2 mM DTT, 
10% Glycerol at pH 7.5).  The cleavage was performed by incubating protein in the 
presence of 1.5 % PreScission protease (kindly provided by Dr. Yan Jessie Zhang, 
Department of Chemistry and Biochemistry, University of Texas at Austin) at 4 ºC 
overnight with gentle shaking.  The cleavage was confirmed by running the protein in 10% 
SDS-PAGE.   
Activation of PERK 
 After overnight protease cleavage, the total protein was collected and further 
incubated with 4 mM ATP and 10 mM MgCl2 for additional 3 hours on the ice for 
activation.  The activated PERK was then applied to HiPrep 26/10 Desalting column (GE 
Healthcare) pre-equilibrated with anion exchange buffer (50 mM Tris pH 8.0, 10 mM 
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NaCl, 0.1 mM EDTA, and 0.1 mM EGTA, 0.1% β-mercaptoethanol).  The excess ATP 
was removed and the eluted protein fractions from HiPrep 26/10 Desalting column were 
followed by Mono-Q HR 10/10 anion exchange chromatography. 
MonoQ 10/10 anion exchange chromatography 
 The cleaved and activated protein was applied to Mono-Q HR 10/10 anion 
exchange column pre-equilibrated with anion exchange buffer (50 mM Tris pH 8.0, 10 mM 
NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% β-mercaptoethanol).  The column was 
developed with a gradient of 0.15-1 M NaCl over 17 column volumes at a flow rate of 2 
mL/min.  The collected peak fractions were analyzed by SDS-PAGE and the fractions 
containing cleaved PERK were collected and dialyzed against storage buffer (25 mM 
HEPES, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 10% Glycerol at pH 
7.5).  The dialyzed protein were concentrated using Amicon Ultra-15 centrifugal filter unit 
(10,000 NMWL) (Millipore), flash frozen in small aliquots in liquid nitrogen and were 
stored at -80 ºC.  The concentration of the protein was established based on the absorbance 
at 280 nm (A280) in spectrophotometer using the extinction coefficient of 97,150 cm
-1M-1 
and path length of 1 cm. 
 
Expression and purification of eIF2α 
 The codon-optimized human eIF2α (4-314) in pET30a vector (pET30a-heIF2aopt) 
was generously provided by Dr. Gerhard Wagner (Department of Biological Chemistry 
and Molecular Pharmacology, Harvard Medical School, Boston, MA).  The BL21 (DE3) 
E. coli strain (Invitrogen) was used for protein expression.  Cells were co-transformed with 
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the expression plasmid for the human eIF2α and the plasmid pG-Tf2 (a kind gift from Dr. 
Gerhard Wagner) which carries the expression system for GroEL, GroES, and TF.  A single 
isolated colony was used to inoculate 100 mL of LB media containing 50 µg/mL 
kanamycin and 17 µg/mL chloramphenicol and the culture was grown overnight at 37 °C 
with shaking at 250 rpm.  Next day the overnight culture was diluted 100 fold into 1000 
mL 2xYT media containing same concentrations of antibiotics and were grown at 37 °C 
for 3-5 hours for OD600 to reach 0.6-1.0.  Cultures were induced with 0.1 mM IPTG for 16 
hours at 20 °C.  Then the cells were harvested by centrifugation (5000 rpm for 20 minutes 
at 4 ºC), flash frozen in liquid nitrogen and stored at -80 °C until lysis.  Aliquot of the 
frozen cell pellet from each liter of culture was resuspended in 50 mL lysis buffer (50 mM 
Tris pH 8.0, 250 mM NaCl, 10 mM Imidazole, 0.1% β-mercaptoethanol, 1 % triton X-100 
(v/v), 1 mM benzamidine, 0.1 mM PMSF, 0.1 mM TPCK and 0.1 mg/mL lysozyme) and 
sonicated for a total of 20 minutes at 5 second pulse with 5 second intervals in ice at 4 °C.  
The lysate was centrifuged for 30 minutes at 16,000 rpm at 4 ºC.  The supernatant 
containing the protein fractions were incubated with Ni-NTA beads (Qiagen) for 1 hour at 
4 ºC.  The beads were washed with 100 mL wash buffer (50 mM Tris pH 8.0, 500 mM 
NaCl, 40 mM Imidazole, 0.1% β-mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF and 
0.1 mM TPCK).  The His6 tagged protein was eluted with 20 mL of elution buffer (50 mM 
Tris pH 8.0, 500 mM NaCl, 500 mM Imidazole, 0.1% β-mercaptoethanol, 1 mM 
benzamidine, 0.1 mM PMSF and 0.1 mM TPCK).  The eluted protein was then loaded into 
HiLoad 16/60 Superdex-75 (GE Healthcare) gel filtration chromatography that was pre-
equilibrated with gel filtration buffer (20 mM HEPES, 200mM NaCl, 2mM DTT, 10% 
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Glycerol at pH 7.5).  The protein was run over 1.2 column volume at a flow rate of 1 
mL/min.  The collected peak fractions were analyzed by SDS-PAGE and the fractions 
containing human eIF2α were collected and dialyzed against storage buffer.  The dialyzed 
protein were concentrated using Amicon Ultra-15 centrifugal filter unit (10,000 NMWL) 
(Millipore), flash frozen in small aliquots in liquid nitrogen and were stored at -80 ºC.  
 
Peptide Synthesis 
 Peptide substrate for PERK (5-FAM-Arg-Ser-Arg-Arg-Gly-Ser-Leu-Asn-Lys-Ser-
Arg-OH) was identified by peptide microarray analysis at Pfizer (Oncology PGRD, La 
Jolla, CA).  This peptide was synthesized, purified by HPLC and purchased from AnaSpec 
(San Jose, CA).  
 
Substrate dependence assays 
eIF2α dependence assays were performed using 20 nM PERK and several 
concentrations of eIF2α (0-50 μM) in assay buffer containing 25 mM HEPES pH 7.5, 50 
mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 10 mM MgCl2, 40 µg/ml BSA and 
0-1000 µM [-32P] ATP (specific activity = 1000 cpm/pmol) in a final reaction volume of 
100 µL.  The reaction mixture was incubated at 30 ˚C for 10 minutes before the reaction 
was initiated by addition of [-32P] ATP.  10 µl aliquots were taken and spotted into P81 
phosphocellulose papers at fixed time point intervals.  The papers were washed with 50 
mM phosphoric acid (3 times for 20 minutes each) and then dried following acetone wash.  
The amounts of radiolabelled phospho- eIF2α were determined by counting the associated 
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counts/min on a synctillation counter (Packard 1500) at an σ value of 2. Kinase activity 
was determined by calculating the rate of phosphorylation of eIF2α (μM.s-1), and the data 











 Equation 4.1 
The parameters are defined as follows: v, initial velocity; app
maxV , apparent maximum 
velocity; [S], concentration of varied substrate; 
app
MK , apparent substrate concentration 
required to achieve half maximal activity. 
 
Compound libraries and Screening Facilities   
 Compound libraries and automation facilities for high throughput screening (HTS) 
were provided by Texas Institute for Drug and Diagnostic Development (TI3D) facility at 
the University of Texas at Austin.  TI-3D has several compound libraries for high 
throughput screening.  These include: Chembridge Kinase set of 11,250 compounds, 
Chembridge fragment set of 4,000 compounds, NCC clinical collection of 446 compounds, 
Maybridge HitFinder V.9 of 14,400 compounds MicroSource Spectrum of 2,000 
compounds, Target focused kinase set of 600 compounds.  All compounds were stored at 
-80 °C as 10 mM stock in 100% DMSO.   
 
Luminescence assay optimization 
Initially, assays were performed manually in white 96-well plates by varying 
reagent (enzyme, ATP, or peptide) concentrations or reaction time to determine the 
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optimum condition.  In detail, 60 µL of the assay mixture (enzyme and peptide diluted in 
assay buffer) was pipetted into a plate, followed by the addition of 40 µL ATP to initiate 
the enzymatic reaction.  After incubating at room temperature for various times, 100 µL of 
the Kinase-Glo Luminescent Kinase assay kit prepared according to the manufacturer’s 
protocol (Promega) was added and the luminescence was measured 10 minutes later. 
Finally, the Kinase-Glo Luminescent Kinase Assay (Promega) has been optimized to be 
done in a 10 µl volume in 384 well plate at room temperature in assay buffer (25 mM 
HEPES pH7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 10 mM MgCl2, 
20 µg/ml BSA) containing 20 nM PERK, 200 µM peptide substrate (5-FAM-
RSRRGSLNKSR) and each tested compound in 0.25% DMSO and 0.01% Triton.  The 
reaction mixtures were incubated at room temperature for 30 minutes before initiation with 
1 µM ATP.  As controls, either all components except PERK or ATP alone were used.  
Luminescent kinase assay measures kinase activity by quantitating the amount of ATP 
remaining in solution following a kinase reaction.  After 2 hours, 10 µl of Kinase-Glo assay 
mix was added.  The kinase reaction was quenched and luminescence was measured on an 
Envision plate reader.   
 
High Throughput Screen (HTS) 
A high throughput screening facility was provided by TI-3D (Texas institutes for 
drug and diagnostic development) at University of Texas-Austin. TI-3D has an automated 
liquid handling system (Perkin Elmer) which can perform assays in 384 well plates and 
Envision plate reader (Perkin Elmer) that can read luminescence signal.  All the libraries 
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were screened at 25 µM final concentration except the Chembridge fragment set which 
was screened at 500 µM and Target focused kinase library that was screened at 3 different 
concentrations (1, 5, 25 µM).  Assays were conducted in 10 µl reaction volume at room 
temperature in assay buffer (25 mM HEPES pH7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 2 mM DTT, 10 mM MgCl2, 20 µg/ml BSA) containing 20 nM PERK, 200 µM 
peptide substrate and 1 µM ATP in 0.25% DMSO and 0.01% Triton.  Rows 1 and 2 
(positive controls) contained enzyme but no compounds whereas rows 23 and 24 (negative 
controls) contained no enzyme or compounds.  Rows 3 to 22 contained enzyme as well as 
the compounds to be screened.  First, 5 µl of assay reaction (all components except ATP 
and inhibitor) was added to the 384 well plates except for the negative control which 
contain the same assay mix except the enzyme and peptide.  Then 1 µl of the 10X inhibitor 
or DMSO only (controls) was added to the wells.  The enzyme-inhibitor mix was allowed 
to incubate at room temperature for 30 minutes before starting the reaction with 4 µl of 
ATP.  After adding ATP, the mixture was incubated at room temperature for 2 hours.  Then, 
10 µl of Kinase-Glo reagent (Promega) was added to each well, and the luminescence 
signal was read on the Envision plate reader for 10 minutes.  Approximately 104 
compounds showed greater than 30% inhibition. 
 
DMSO tolerance 
 Assays to test DMSO tolerance were performed in assay buffer (25 mM HEPES 
pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 10 mM MgCl2 and 40 
µg/mL BSA) containing 20 nM PERK, 1 µM ATP, 200 µM peptide substrate and different 
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concentrations of DMSO (0, 1, 2, 3, 5, 10%) in 100 µl volume at room temperature.  Assays 
were started with the addition of ATP.  
 
Confirmation Screen  
Compounds demonstrating above 30% activity in the rescreen were further 
confirmed by radioactive screen.  Compound final concentrations were 100 µM for 
Fragment library and 1, 5, 25 µM for all other libraries.  Assays were performed at room 
temperature in 100 µl volume in 96 well plate format.  All other assay conditions were 
maintained similar except that the radioactive assays were performed using protein 
substrate at 5 µM.  First, 10 µl of compounds were pipetted into the wells of 96 well plates.  
Then 70 µl of the assay mix (enzyme, peptide, and buffer) were added into each wells.  The 
first row contained enzyme but no inhibitors (positive controls) and the last row contained 
no enzyme or inhibitors (negative control).  The enzyme-inhibitor mix was incubated in a 
volume of 90 µL per well in 96-well plate at room temperature for 30 minutes.  The 
reactions were initiated by the addition of 10 µL [γ-32P] ATP, adjusting the ATP 
concentration to 100 μM (100-1000 c.p.m. pmol-1) for PERK.  The reaction was incubated 
at room temperature for 10 minutes and then quenched by transferring 80 μL of reaction 
mixture to each well of a P81 96-well filter plate (Unifilter, Whatman) containing 200 μL 
of 0.1 M phosphoric acid solution.  The P81 filter plate was washed 7-8 times with 200-
300 mL of 0.1 M phosphoric acid solution to get rid of excess ATP, dried with acetone 
followed by the addition of 20 mL of scintillation cocktail.  The counts in each wells were 
read using MicroBeta®TriLux liquid scintillation counter (Perkin Elmer).  For the 
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compounds that showed greater than 50% activities, dose response assays were performed 
at several concentrations of the compound to determine IC50.  
 
In Vitro Kinase Inhibition Assay  
 Kinase inhibition assays were conducted at 30 °C in assay buffer (25 mM HEPES 
buffer-pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT and 10 μg mL-1 
BSA), containing 300 μM [γ-32P] ATP (100-1000 c.p.m. pmol-1), 11 mM MgCl2 and 
different concentrations of each compound in a final total volume of 70 µL, containing 5-
10 % DMSO and 0.03% Brij-35 surfactant.  Activity was assessed at different compound 
concentrations by the measurement of initial rates, where the total product formation 
represented less than 10% of the initial substrate concentrations.  Every reaction was 
initiated by the addition of ATP.  At set time points (0.5, 1, 1.5, 2, 4 min), 10 μl aliquots 
were taken from every reaction and spotted onto 2×2 cm2 squares of P81 cellulose paper; 
the papers were washed 3 times for 15 minutes each in 50 mM phosphoric acid (H3PO4), 
followed by a pure acetone wash, then dried.  The amount of labeled protein was 
determined by counting the associated c.p.m. on a Packard 1500 scintillation counter at a 
sigma value of 2.  Dose-response curves for data conforming to inhibition were fitted to 
equation 4.2.     
                                                                Equation 4.2 
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Cell culture  
HEK293T cells were maintained in DMEM (Invitrogen) supplemented with 2 mM 
L-glutamine (Invitrogen), 10% (v/v) FBS-US grade (Invitrogen), 100 g mL-1 streptomycin 
(Sigma-Aldrich) and 100 U mL-1 penicillin (Sigma-Aldrich).  Cells were cultured at 37 °C 
in a humidified 5% CO2 incubator.  The pancreatic carcinoma MiaPaCa-2 cell line was 
obtained from American Type Culture Collection (Manassas VA).  MiaPaCa-2 cells were 
grown in DMEM medium adjusted to contain 4 mmol/L L-glutamine, 4.5 g/L glucose, 10% 
(v/v) fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin.  Cell line 
was maintained in a humidified incubator containing 5% CO2 at 37 °C.  
 
Cell Proliferation Assay 
 Cell proliferation was assessed using MTS assay (CellTiter 96® AQueous Assay, 
Promega, WI).  Cells were seeded in 96-well plates at a density of 2 X 103 cells per well in 
100 µl medium.  Next day cells were treated with different concentrations of 4 PERK 
inhibitors (compound 1-4) followed by addition of 0.15 µg/mL tunicamycin to induce ER 
stress.  After 72 hours incubation, 20% MTS reagent was added into the culture medium.  
After 2-4 hours further incubation, the change in tetrazolium salts into formazan was 
determined by measuring the absorbance at 490 nm using kinetic microplate reader 
(Molecular Devices Corporation, Sunnyvale, CA). 
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Colony Formation Assay 
The inhibition of the colony-forming ability of MiaPaCa-2 cells was assayed by 
seeding cells in complete medium into 100-mm tissue culture plates and cells were allowed 
to grow to reach 90% confluence.  Cells were then treated with various concentration of 
compounds in complete medium for 1 hour, followed by addition of 5 µg/mL tunicamycin 
for an additional 6 hours to induce ER-stress.  DMSO was used as a control.  Treated cells 
were harvested using trypsin, counted and a specific number of cells (500 cells) were plated 
in 50 mm petri dishes.  They were cultured at 37 °C with 5% CO2 and saturated humidity 
conditions for 10 days.  After 10 days, the medium was removed and cells were rinsed in 
PBS, and fixed in 3% (v/v) acetic acid, 10% (v/v) methanol for 2 minutes.  Then fixed 
solution was discarded and 0.2% (w/v) crystal violet staining solution was added and 
stained for 30 minutes.  They were washed with water slowly and dried in the air and 
colonies were counted manually. Colonies were defined as ≥50 cells. 
 
Western blot analysis 
MiaPaCa-2 cells were treated with DMSO or various concentrations of compound 
3 for 1 hour, followed by addition of 5 µg/ml tunicamycin (Sigma) for an additional 5 hours 
to induce ER-stress.  After respective times, the cells were trypsinized and collected by 
centrifugation.  After washing the cells with PBS (Invitrogen), the lysates were prepared 
in cold RIPA buffer containing protease inhibitors (Roche Diagnostics, Indianapolis, IN).  
Then cell lysates were cleared and collected by centrifugation.  The protein concentration 
was measured by Bradford analysis (Bio-Rad).  Lysates containing 30 µg of total protein 
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were fractionated on a 10% SDS polyacrylamide gel and transferred to Hybond-P PVDF 
Membrane (GE Healthcare) using Bio-Rad’s Mini-PROTEAN system.  The membranes 
were blocked with 5% dry milk in Tris-buffered saline-Tween 20 (TBST) for 1 hour at 
room temperature.  Blots were incubated with primary antibodies overnight at 4 ºC using 
1:1000 anti-total PERK (R&D System); 1:1000 anti-total eIF2α; 1:1000 anti-phospho 
eIF2α (Ser 51); 1:500 anti-ATF4; 1:500 anti-CHOP (Cell Signaling Technology) and anti-
actin (Millipore).  Either anti-goat (Thermo Scientific) anti-rabbit (Bio-Rad) or anti-mouse 
(Cell Signaling Technology) horseradish peroxidase-conjugated secondary antibodies, 
ECL Plus™  and western blotting reagents (GE Healthcare) were employed to develop the 
blots. 
 
4.4 RESULTS AND DISCUSSION 
Expression and purification of active human PERK and eIF2α 
 Human PERK and eIF2α were purified according to the protocol explained earlier 
in the Materials and Methods section.  His-GST-tagged human PERK (541-1116 a.a) was 
expressed in a modified pET28a vector using E. coli strain Rosetta-gami™ 2(DE3).  
Purification was accomplished by three successive chromatography steps: 1) Ni-NTA 
affinity, 2) Cleavage and HiPrep desalting, and 3) Mono Q 10/10 anion exchange.  We 
purified soluble, tag-cleaved human PERK, which has an ability to phosphorylate eIF2α as 
well as a peptide substrate.  The purity of PERK was verified by running the protein on 
10% SDS-PAGE.  The final cleaved PERK runs as an 85-kD protein on SDS-PAGE (figure 
4.1C).  His6-tagged human eIF2α (4-314 a.a) was overexpressed in E. coli strain BL21 
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(DE3) and purified using Ni-NTA affinity chromatography, followed by a gel filtration 
column.  The recombinant human eIF2α runs as a 37-kD protein in SDS-PAGE (figure 
4.1D).  
 
Determination of kinetic parameters of PERK 
 To analyze the ability of the purified kinase to phosphorylate its substrate, eIF2α, 
dose response assays were performed with 20 nM PERK and several concentrations of 
eIF2α (0-50 μM) as described under ‘4.3 Materials and Methods’.  Initial velocity data at 
different concentrations of eIF2α and saturating ATP concentration were fitted using 
equation 4.1 and kinetic parameters for PERK phosphorylating eIF2α determined (figure 
4.2).  The recombinant human PERK expressed in bacteria phosphorylates eIF2α, with a 
half maximal activity achieved at 8.1±3.2 µM and a catalytic constant of appcatk  = 
0.28±0.035 s-1.   
 
Optimization of luminescent kinase assay for screening 
To screen chemical libraries efficiently, a suitable detection technology must be 
chosen(146).  The Kinase-Glo Luminescent Kinase Assay, a nonradioactive, homogeneous, 
ATP quantitative kit useful for kinase activity detection, is available from Promega 
(Madison, WI).  ATP is a universal substrate for kinases.  Thus, we decided to use the 
Kinase-Glo assay in order to determine kinase activity in an HTS format.  In order to 
optimize the kinase reaction for screening, a set of experiments were conducted to 
determine the optimal concentration of ATP, substrate, and kinase necessary for the 
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reaction.  We optimized HTS assay conditions using both 96 well plates and 384 well plates 
(figure 4.3).   
The reaction has been optimized to be done in a 10 µl volume in 384 well plate at 
room temperature in assay buffer (25 mM HEPES pH7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA, 2 mM DTT, 10 mM MgCl2, 20 µg/ml BSA) containing 20 nM PERK, 200 
µM peptide substrate (5-FAM-RSRRGSLNKSR) and each tested compound in 0.25% 
DMSO and 0.01% Triton.  The reaction mixtures were incubated at room temperature for 
30 minutes before initiation with 1 µM ATP.  As controls, either all components except 
PERK or ATP alone were used.  Luminescent kinase assay measures kinase activity by 
quantitating the amount of ATP remaining in solution following a kinase reaction.  After 2 
hours, 10 µl of Kinase-Glo assay mix was added.  The kinase reaction was quenched and 
luminescence was measured on an Envision plate reader.  ATP remaining at the time that 
the reagent is added is used as a substrate by the luciferase to catalyze the mono-
oxygenation of luciferin (Scheme 4.2).  The luminescent signal correlates directly to the 
amount of ATP present and inversely correlates with the amount of kinase activity.  High 
throughput screening assays usually contain small amounts of additives such as DMSO or 
detergents.  Since many small molecule compounds are not soluble in aqueous buffer, 
addition of small amount of DMSO can enhance the solubility of the compounds.  In 
addition, detergents such as Brij-35 or Triton are also widely used since they can enhance 
the stability of the enzyme.  These additives can bind to the enzyme and interfere the 
enzyme activity.  Therefore DMSO tolerance test was performed by varying DMSO 
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concentration (0 to 10%) to see if this factor had any effect on the enzymatic activity.  As 




Scheme 4.2. Principle of the Kinase-Glo luminescent kinase assay. 
 
High throughput screening of small molecule libraries  
HTS was performed in 384 well plates using the optimized assay conditions, as 
described earlier.  A total of ~30,000 small compounds from both focused and diverse 
libraries were screened for potential hits.  All the libraries were screened at 25 µM final 
concentration except the Chembridge fragment set which was screened at 500 µM.  
Compounds showing greater than 50% activity in the assay were considered as hits.  Out 
of 32,096 compounds screened, ~104 compounds showed greater than 50% activity.  HTS 
is often populated with false-hits, which can result from the variability in the assay itself.  
The suitability of the HTS assay is often determined by a statistical measurement called 
the Z’ factor which takes into account the mean and standard deviation values for the 
positive and negative reference controls (147).  A Z’ value between 0.5 and 1 is generally 
considered as an indicator of a quality assay.  The calculated Z’ values for our screening 
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were greater than 0.5 for all plates which suggests that there is a large separation of data 
points between the baseline and the positive signal.  
Both focused and diverse libraries of small compounds were screened for potential 
hits.  The focused library was selected utilizing a ligand-based pharmacophore selection 
method that ranked compounds based on pharmacophores that promote interaction with 
the ATP binding site of protein kinases (Chembridge Corporation).  A Target focused 
Kinase set ~600 known kinase inhibitors was also screened.  As expected, several hits were 
obtained from the kinase focused libraries (Chembridge Kinase set and Target focused 
Kinase set) (figures 4.7 and 4.8).  A Fragment library was also screened at 500 µM to yield 
several hits (figures 4.5).  The Fragment library contains simpler and less functionalized 
compounds (MW <300 Da).  As a consequence, hits from the fragment library do not tend 
to bind tightly (Kd values in the micro- to milli-molar range).  This suggests that kinase-
focused libraries may be suitable for targeting PERK.  The main task we faced following 
the screen was to verify the hits.  Some compounds may interfere with luminescence 
leading to false-positive hits, thus, a different type of kinase assay such as a 32P assay was 
used for confirmation. 
 
Hit confirmation screen by radiometric assay 
Based on the inhibitory activities of the compounds, we prioritized hits in the 
original screens to validate them.  Confirmation screen was performed by radioactive assay 
using the protein substrate, eIF2α.  All enzyme-inhibitor mixtures were incubated for 30 
minutes before starting the reaction with [-32P] ATP.  Since some compounds were found 
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to be insoluble, the final DMSO concentration was increased to 5% to enhance better 
solubility.  Hits were re-screened at concentrations of 0.5 and 25 µM except the fragments, 
which were tested at 500 µM.  Compounds that showed more than 50 % inhibition at 25 
µM in the counter screen, were further assessed in dose-response assays in the presence of 
0.01% triton X-100.  It is known that many compounds form aggregates in aqueous 
solutions and inhibit the enzyme by non-specifically binding to them (148-150).  The presence 
of small amounts of non-ionic detergent such as triton X-100 can often attenuate the 
inhibition if the compound is acting by aggregation (148-150).  Therefore, the purpose of triton 
X-100 is to get rid of the promiscuous inhibitors.  
Among several hits exhibiting more than 50% inhibition at a concentration of 25 
µM, four small molecules inhibited PERK with nanomolar IC50.  The four inhibitors were 
all found in the target focused kinase library.  Their inhibition rates from both initial and 
validation screening were calculated as a percentage with respect to the control value 
(table 4.1 and 4.2).  The dose-response curves are plotted and fitted using equation 4.2.  As 
seen in figure 4.9, compound 3 is the most potent inhibitor of PERK with an IC50 of 19 nM 
while compounds 1, 2, and 4 show IC50 values of 68, 300, and 45 nM respectively.  
 
Effect of compounds (1-4) on PERK autophosphorylation 
In addition, we examined whether these compounds are capable of inhibiting PERK 
autophosphorylation by using a phosphate free form of PERK.  As shown in figure 4.10A, 
phosphate free PERK was successfully prepared by treating with lambda phosphatase in 
vitro and purified through size-exclusion chromatography.  To test the capability of the 
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produced phosphate free PERK to autophosphorylate in vitro after removal of the 
phosphates, 200 nM of phosphate free PERK was exposed to 1 mM 32P-ATP in the 
presence of 10 mM MgCl2 for 0 to 30 minutes and the phosphate addition was visualized 
by autoradiography.  Phosphate free PERK was successfully autophosphorylated in vitro 
(figure 4.10B), confirming that this form of the enzyme is suitable to test the effects of the 
compound (1-4) on PERK autophosphorylation.  Figure 4.11 displays the dose-responsive 
curves of compounds (1-4) against PERK autophosphorylation.  As seen in table 4.3, 
compounds 1 and 2 inhibited PERK autophosphorylation with IC50 values of 74 and 140 
nM respectively.  On the other hand, different mode of inhibition was observed in 
compound 3 and 4.  In particular, compound 3 showed more than 60 fold difference 
between IC50 values of PERK autophosphorylation (~1200 nM) and eIF2α phosphorylation 
(~19 nM) suggesting that compound 3 appears to have a distinct mode of binding.  Our 
data suggest that compound 3 may be a starting point for the development of potent and 
selective small molecules capable of inhibiting PERK. 
 
Characterization of PERK inhibitors on cellular activity 
In order to confirm that our in vitro results using purified enzyme correlates with 
cellular studies, we examined the ability of compounds (1-4) to inhibit PERK activity in 
HEK293T cells.  PERK activity was assessed in a gel-based assay in the presence of each 
inhibitor.  The effect of each compound on the phosphorylation of eIF2α, an in vivo 
substrate of PERK, as well as on the autophosphorylation of PERK was tested following 
stimulation of PERK by a chemical inducer of the UPR, and visualized by western blot 
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analysis.  To validate the ability of the selected anti-p-eIF2α (Ser51) antibody to detect the 
phosphorylated form of eIF2α, we examined the effect of compounds (1-4) on the 
phosphorylation of recombinant eIF2α by PERK in-vitro using this antibody in a western 
blot based assay.  As showing in figure 4.12, levels of phosphorylated eIF2α were 
significantly decreased when incubated with compounds (1-4) compared to the control.   
PERK is up-regulated in cells upon treatment with pharmacological agents that 
disrupt the Ca2+ balance (thapsigargin), protein folding (DTT), or N-linked glycosylation 
(tunicamycin) in the endoplasmic reticulum (125).  We used 1 µM of thapsigargin (151, 152) as 
an ER stress inducer.  As expected, compounds 1-4 showed inhibition of eIF2α 
phosphorylation in the HEK293T cells, with compounds 3 and 4 exhibiting almost 
complete inhibition at a concentration of 5 µM (figure 4.13).   
A demonstration of an inhibition of PERK autophosphorylation with the 4 
inhibitors in HEK293T cells was difficult due to the lack of a reliable phospho-specific 
antibody to human PERK.  Thus, autophosphorylation of PERK was visualized by SDS-
PAGE by mobility shift detection of the phosphorylated protein using a total anti-PERK 
antibody.  Treatment of HEK293T cells with 1 µM thapsigargin for 2 hours leads to 
activation and autophosphorylation of PERK.  Figure 4.S1 displays an example of the 
inhibition of PERK upon treatment with compound 3.  The level of PERK phosphorylation 
started to decrease at the concentration of ~ 10 µM.  Surprisingly, at the higher 
concentration, expression level of PERK itself was significantly suppressed (figure 4.S1, 
supplementary materials).  Previous studies suggest that many kinases are activated upon 
cleavage by caspases (153).  In fact another eIF2α kinase, PKR (protein kinase double-
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stranded RNA-dependent) is cleaved by mammalian caspase and the cleaved PKR is active 
in phosphorylating its substrate (154).  Likewise, high concentration of PERK inhibitors may 
trigger more stress in cells and escalated ER stress might cause cleavage or degradation of 
PERK.  Future studies to understand the possible underlying mechanism of this result will 
be necessary. 
 
Investigating the effect of compound 3 (TG101348) in pancreatic cancer cells 
Effect of compound 3 (TG101348) on cell proliferation and colony formation 
It has been reported by Bobrovnikova-Marjon et al. that knockdown of PERK by 
shRNA in human breast and esophageal carcinoma cells triggers a cell cycle delay, 
resulting in a significant decrease (50% reduction) in cell proliferation (155).  Moreover, 
PERK-deficient MEF cells generated tumors with a significantly reduced volume (16 fold) 
relative to PERK-positive MEF cells (80) suggesting that PERK promotes cancer cell 
proliferation and tumor growth.  
Therefore, the effectiveness of compound 3 in inhibiting the growth of human 
pancreatic carcinoma cell lines was investigated.  MiaPaCa-2 cells were treated with 
different doses of compound 3 to determine whether or not this compound might have anti-
proliferative effects on pancreatic cancer cells during the log phase of growth.  MiaPaCa-
2 cells were cultured with increasing concentrations of the compound followed by 
incubation with the ER stress inducer, tunicamycin for 72 hours.  Tunicamycin perturbs 
ER homeostasis by affecting N-linked glycosylation of proteins.  Then cell proliferation 
was assessed by an MTS assay (Promega).  This assay relies on the ability of viable cells 
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to convert a soluble tetrazolium salt [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS] to a formazan product, 
which then can be quantitated using a spectrophotometer.  Control cells were treated with 
equivalent concentrations of DMSO in the absence of inhibitors.  As shown in figure 4.14, 
incubation with compound 3 in the presence of tunicamycin for 72 hours significantly 
inhibited the proliferation of MiaPaCa-2 cells.  Treatment of compound 3 resulted in a 
dose-dependent inhibition of cell proliferation with a 50% inhibitory concentration (IC50) 
value of ~0.8 μM in the presence of tunicamycin (0.15 µg/ml). In the absence of 
tunicamycin, the IC50 value was ~15 μM.  Compounds (1,2 and 4) were also effectively 
anti-proliferative in ER stressed MiaPaCa-2 cells, but higher concentration of these 
compounds were required to reach 50% inhibition in the absence of ER stress (data not 
shown).  There was no significant cytotoxic effect when MiaPaCa-2 cells were solely 
treated with tunicamycin (0.15 µg/ml) without compounds.  The cytotoxic effects of 
compounds on long-term survival were further confirmed with a clonogenic assay.  This 
assay is also referred to as an anchorage-dependent colony formation assay.  It measures 
the ability of a single cell to grow into a colony (usually defined as >50 cells) and its ability 
to undergo unlimited division.  Cancer cells are characterized by unrestricted growth due 
to loss of contact inhibition while normal, untransformed cell growth is arrested when they 
come into contact with each other.  Thus, this clonogenic assay is an indirect measure of 
the tendency of MiaPaCa-2 cells to undergo neoplastic transformation.  MiaPaCa-2 cells 
were treated with varying concentrations (5, 10, 25, 50 µM) of compound 3 under 
tunicamycin-induced stress for 6 hours.  Next, the medium was aspirated and washed, and 
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cells were trypsinized.  Then, cells were counted, re-plated onto 60 mm dishes at initial 
cell concentrations of 500 cells/well and allowed to grow for an additional 15 days with 
inhibitor-free medium.  As seen in figure 4.15, during the 15-day culture period, exposure 
of cells to compound 3 reduced the colony-forming ability relative to cells exposed to 
tunicamycin alone.  Clonogenicity of MiaPaCa-2 cells treated with compound 3 showed 
50% inhibition that was clearly evident at 10 µM.  In addition, treatment with both 
compound 1 and 2 led to nearly 100% cell death even at the lowest concentration, 5 µM 
(data not shown). 
 
Effect of compound 3 (TG101348) on PERK downstream signaling pathway 
To further elucidate the mechanism of PERK inhibitor-mediated ER stress response 
signaling in pancreatic cancer cell lines, we evaluated key UPR signaling molecules by 
Western blotting.  We selected compound 3 for use in cellular studies based on its potency 
as an inhibitor of PERK activity in MiaPaCa-2 cells.  As expected, pre-treatment of 
MiaPaCa-2 cells with compound 3 in the presence of the ER stress inducer, tunicamycin 
resulted in the inhibition of PERK activation, as well as PERK expression.  In addition, 
treatment with compound 3 repressed PERK-mediated UPR signaling in a dose-dependent 
fashion. 
It is generally known that tunicamycin activates the UPR through inhibition of N-
linked glycosylation, which triggers ER stress due to the accumulation of misfolded 
proteins.  As shown in figure 4.16, tunicamycin alone induced activation of PERK, which 
was visualized by a mobility shift detection of phosphorylated proteins on SDS-PAGE.  
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Furthermore, treatment with tunicamycin markedly increased the levels of ATF4 and 
CHOP.  The treatment with compound 3 significantly suppressed the expression of PERK 
in the MiaPaCa-2 cells and this expression pattern was similar to that seen in figure 4.S1.  
This decrease in PERK expression by compound 3 may be due to the activation of caspase-
driven proteolytic activity associated with cells undergoing apoptosis triggered by ER 
stress.  The molecular mechanism underlying this observation needs to be investigated 
further.  Western blot analysis of MiaPaCa-2 cells treated with compound 3 revealed 
decreases in downstream targets for PERK signaling, such as ATF4, and CHOP expression, 
compared to cells treated with tunicamycin alone (figure 4.16), suggesting a cause and 
effect relationship between compound 3 and down-regulation of UPR signaling.  
Interestingly, however compound 3 did not inhibit phospho-eIF2α, even at the highest 
concentration used.  This suggests that other eIF2α kinases, such as GCN2, PKR and HRI 
may contribute to the regulation of eIF2α in pancreatic cancer cells.  Collectively, however 
our results suggest that compound 3 disrupts the regulation of the UPR in pancreatic cancer 
cells subject to ER stress by tunicamycin.  TG101348 is also known to inhibit the non-
receptor tyrosine kinase, JAK2(156-158), which is associated with the promotion of growth 
and division of mammalian cells including blood cell and found in almost every cell type 
(158, 159).  It is essential for signaling through a variety of cytokine receptors, such as those 
that bind growth hormone, prolactin, erythropoietin, and thrombopoietin (158-162).  Therefore 




Scheme 4.3. Dual inhibition of compound 3 (TG101348). 
 
Biphasic effects of PERK specific inhibitor (GSK2606414) 
Recently, a group from GlaxoSmithKline developed and discovered a specific 
PERK inhibitor, GSK 260414, which exhibited antitumor activity against human 
pancreatic xenograft tumors (125).  According to the authors, this PERK inhibitor has an 
IC50 of ~0.4 nM in vitro and an IC50 of ~30 nM for inhibition of PERK autophosphorylation 
in a cellular assay.  Moreover this compound is orally available and highly selective for 
PERK with a selectivity of >385-fold for PERK over a panel of 294 kinases including three 
other eIF2α kinases.  We synthesized this highly specific PERK inhibitor (GSK2606414) 
to compare with our inhibitors and to use in control experiments.  In the beginning, we 
synthesized GSK260414 according to Axten et al. and confirmed its structure by 1H NMR, 
13C NMR and mass spectrometry (124).  The ability of GSK2606414 to inhibit PERK was 
confirmed in an in vitro dose response assay.  Next we examined its cytotoxicity in human 
pancreatic cancer cells (MiaPaCa-2) by using an MTS assay to compare with results we 
obtained from our hits (compound 1-4).  MiaPaCa-2 cells were treated with various 
concentrations of GSK2606414 under stressed condition by tunicamycin and MTS assays 
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were performed using the same protocol described above.  It showed remarkably anti-
proliferative activity in ER-stressed MiaPaCa-2 cells at concentrations ranging from 0.05 
to 1 µM.  The maximum inhibitory effect was observed at 0.5-1 µM.  The majority of 
MiaPaCa-2 cells treated at 500 nM exhibited ≤15% viability compared with their 
respective controls.  Surprisingly, this anti-proliferative effect was reversed when cells 
were incubated at concentrations greater than 1 μM as shown in figure 4.17 (indicated by 
red curve).  
We found that GSK2606414 possessed an inhibitory effect when added at 0.05–1 
μM concentration, but it became growth stimulatory when its concentration was further 
increased to 25 µM, implying that PERK inhibition by GSK2606414 might trigger a 
compensatory effect that in turn, leads to a paradoxical and biphasic proliferative response.  
Furthermore, in the absence of ER stressor, tunicamycin, there were no significant effects 
of GSK2606414 on cell growth as seen in the blue color in figure 4.17.  The rebound effect 
was also observed in a colony formation assay (figure 4.18).  This biphasic response was 
unexpected since Axten et al. reported an anti-proliferative activity of the PERK inhibitor 
in a 3-day proliferation assay against multiple human tumor cell lines, including pancreatic 
cancer cells, as well as primary human microvascular endothelial cells.  The authors also 
did not report significant effects on the growth of any of these cells in the absence of 
exogeneous ER stress inducers, suggesting that the UPR is not induced under normal cell 
culture conditions.   
We wondered whether PERK signaling was also biphasic.  Therefore, we assessed 
the influence of varying doses of GSK2606414 on PERK-dependent signaling in the 
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MiaPaCa-2 cells by western blotting analysis.  As shown in figure 4.19, CHOP showed a 
biphasic pattern of expression in response to GSK2606414.  Indeed, lower concentrations 
(1, 3 µM) of GSK2606414 decreased CHOP protein expression levels compared to the 
control, whereas higher doses counteracted this effect.  We observed a similar result on p-
eIF2α expression; at a GSK2606414 concentration of 3 µM expression of p-eIF2α was 
minimal.  The biphasic pattern of proliferation in tunicamycin-stressed cells correlates with 
CHOP expression.  Generally CHOP is thought to be a pro-apoptotic transcription factor 
induced by ER stress (50).  Hence CHOP expression is generally considered as an ER stress 
induced cell death marker (71, 94).  Our observation raises the possibility that CHOP may 
promote MiaPaCa-2 cell proliferation in the presence of stress, despite its apoptotic 
function.  As a transcription factor, CHOP itself seems unlikely to be intrinsically 
apoptotic; it more likely regulates the expression of downstream genes that facilitate either 
cell death or cell survival depending on the extent of ER stress and cell fate.  The 
compensatory feedback signaling may be triggered through other UPR molecules such as 
ATF6 and IRE 1, which rescue pancreatic cancer cells from cell death.   
Axten et.al reported that the PERK inhibitor inhibited PERK activity in a dose 
dependent manner with an IC50 in the range of 10-30 nM as shown by the inhibition of 
stress-induced PERK autophosphorylation, as well as decreases in the downstream 
substrates, eIF2α phosphorylation, ATF4, and CHOP in multiple pancreatic cancer cell 
lines.  It should be noted that the authors tested the GSK compound up to 3 µM, and did 
not report concentrations higher than 3 µM.  In addition, more recently, Cojocari et.al also 
synthesized this PERK inhibitor, GSK2606414, and tested it in their cellular experiments 
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(163).  The authors observed its ability to inhibit PERK autophosphorylation and 
downstream eIF2α phosphorylation following exposure to hypoxia (0.2% O2) or 
thapsigargin (300 nM) in the colon cancer cells (HCT116) and pancreatic ductal carcinoma 
cells (KP4).  The GSK2606414 strongly decreased hypoxia- or thapsigargin-induced 
expression of CHOP in HCT116 cells.  However, the compound was ineffective at 
inhibiting CHOP expression in KP4 cells, but surprisingly sensitized them to thapsigargin-
induced ER stress in a concentration dependent manner.  Under normal growth conditions 
however, GSK2606414 did not affect the proliferation of KP4 cells (163). 
Based on results from ourselves and others pancreatic cells tend to be insensitive to 
PERK inhibition under normal cell culture conditions.  No other group has reported a 
paradoxical biphasic effects of GSK2606414 in the literature.  Therefore, the possible 




Both focused and diverse libraries consisting of almost 30,000 small compounds 
were screened against PERK through luminescent kinase assay.  Approximately, 60 hits 
were identified from the initial high throughput screening and further validated using a 
radioactive based kinase assay.  A total of four small molecules were selected as potential 
inhibitors of PERK with nanomolar IC50’s.  Compound 3, TG101348 showed the most 
marked inhibitory potency in vitro and is a known inhibitor of the kinase JAK2.  Its 
biological effect was further examined in a pancreatic cancer cell line.  TG101348 induced 
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the dose-dependent degradation of PERK as well as the down-regulation of UPR signaling 
(e.g. the induction of ATF4 and CHOP).  Furthermore, TG101348 suppressed pancreatic 
cancer cell proliferation.  Pancreatic cancer cells subject to tunicamycin-induced ER stress 
exhibit a biphasic response to the PERK specific inhibitor GSK2606414.  The basis for this 
observation is unknown, but suggests the potential for synthetic-lethal targeting of cancer 
cells utilizing PERK as an adaptive stress response.  Further studies to understand the 
possible underlying molecular mechanism will be required.  The inhibitors described here 
represent starting points for the development of potent and selective small molecules 





Figure 4.1. Purification of human PERK catalytic domain and eIF2α that were 
expressed in E. coli. 
A, Schematic representation of the full length of PERK.  B, Schematic representation of 
the expressed form of the catalytic domain of PERK. This PERK catalytic domain was 
expressed in E. coli.  C, Left gel, samples from Ni-NTA affinity chromatography were 
resolved by 10% SDS-PAGE: Lane 1, BenchMark™ protein ladder (Invitrogen); Lane 2, 
Protein eluted from Ni-NTA agarose affinity chromatography; Lane 3, Elution fraction 
from the Ni-NTA column was incubated with PreScission protease, resulting in GST-tag 
cleaved PERK.  Right gel, Purified tagless PERK catalytic domain runs as an 85 kDa 
protein on 10% SDS-PAGE.  D, Human eIF2α (4-314 a.a) overexpressed in the bacterial 
cells (BL21) was subjected to Ni–NTA agarose affinity chromatography followed by 
Superdex 200 gel filtration chromatography.  Purified eIF2α runs as a 37 kDa protein on 




Figure 4.2. Analysis of the kinase activity of PERK. 
Human eIF2α dependence assays were performed using 20 nM PERK and 0-50 μM eIF2α 
in a suitable buffer as described under ‘4.3. Materials and Methods’.  The data were fitted 
to Michaelis Menten equation 4.1, where 
app
MK  = 8.1±3.2 µM and 
app
maxV  = 5.6± 0.7 nM.s
-1.  
Kinase activity was determined by measuring the rate of phosphorylation of eIF2α (nM.s-






Figure 4.3. Optimization of luminescent kinase assay. 
HTS assay conditions were optimized in 384 well plates.  Assays were conducted in a 10 
µl reaction volume at room temperature in the assay buffer as described under ‘4.3 
Materials and Methods’.  Assay mixtures were prepared with or without enzyme in the 
presence or absence of 200 µM of peptide and 1 µM ATP.  Positive control = assay buffer 





Figure 4.4. Assay stability in the presence of different concentrations of DMSO. 
Assay mixtures were prepared with or without 200 µM of peptide in the presence of 20 nM 












































Figure 4.9. The effect of compounds 1-4 on the ability of PERK kinase domain to 
phosphorylate eIF2α substrate. 
20 nM active PERK kinase domain was assayed with 8 µM of eIF2α substrate.  Activity 
was assessed at different inhibitor concentrations by the measurement of initial rates at 30 
oC in 25 mM HEPES pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 0.05 M KCl, 
10 mM MgCl2 and 0.2 mM [γ-
32P] ATP.  The reaction was started by the addition of radio 
labeled ATP.  These 4 compounds are potent inhibitors towards PERK (IC50 for 
compounds 1-4 inhibiting eIF2α phosphorylation were 68, 300, 19 and 45 nM 




Figure 4.10. Preparation of phosphate-free PERK kinase domain by treatment with 
lambda phosphatase.  
A, Human PERK kinase domain (541-1116 a.a) overexpressed in the bacterial cells (BL21) 
was subjected to Ni–NTA agarose affinity chromatography and treated with lambda 
phosphatase in vitro at room temperature.  Lane 1, PERK without lambda phosphatase 
treatment; Lane 2, BenchMark™ protein ladder (Invitrogen); Lane 3, Flow-through 1; 
Lane 4, Flow-through 2; Lane 5, Wash; Lane 6, Eluted PERK with lambda phosphatase 






Figure 4.11. The effect of compounds 1-4 on the ability of PERK kinase domain to 
autophosphorylate.  
Initial velocities of  PERK autophosphorylation was measured using 50 nM phosphate free, 
inactive PERK at 30 °C in 25 mM HEPES pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA,  2 mM 
DTT, 0.05 M KCl, 10 mM MgCl2 and 10 µM [γ-
32P] ATP.  IC50 for compounds 1-4 
inhibiting PERK autophosphorylation were 74, 142, 1186 and 398 nM respectively.  The 





Figure 4.12. Test the compounds (1-4) on the phosphorylation of eIF2α in vitro. 
PERK kinase domain (20 nM) was incubated with eIF2α (8 µM) and ATP (1 mM) in the 
assay buffer containing 25 mM HEPES pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 2 mM DTT, 10 mM MgCl2, 40 µg/ml BSA for 10 minutes in the presence of 10 







Figure 4.13. Cellular effect of compounds (1-4) on the phosphorylation of eIF2α in 
HEK293T cells.  
HEK293T cells were pre-treated with different concentrations of each compound (10-100 
µM) followed by UPR induction for 1 hour (1 µM thapsigargin).  Cell lysates were 





Figure 4.14. Compound 3 induces apoptotic death of pancreatic cancer cells. 
Compound 3 reduces the number of viable MiaPaCa-2 cells in culture.  The cells were 
treated with an increasing concentrations of compound 3 in the presence or absence of 
tunicamycin (0.15 µg/mL) for 72 hours, and the fraction of viable cells were determined 
by MTS assay (Promega) according to the protocol described in ‘4.3 Materials and 






Figure 4.15. Compound 3 inhibits colony formation of MiaPaCa-2 cells. 
MiaPaCa-2 cells were treated with various concentrations of compound 3 in complete 
medium for 1 hour, followed by addition of 5 µg/ml tunicamycin for an additional 6 hours 
to induce ER stress.  Treated cells were harvested using trypsinization, and re-plated (500 
cells/ dish) and cultured at 37 °C with 5% CO2 for 10 days.  Images of the colonies formed 





Figure 4.16. Cellular effect of compound 3 on PERK signaling. 
MiaPaCa-2 cells were pre-treated with different concentrations of compound 3 (1-50 µM) 
followed by UPR induction for 5 hours (5 µg/ml tunicamycin).  Cell lysates were analyzed 





Figure 4.17. PERK inhibition by GSK2606414 induces biphasic response in 
pancreatic cancer cell proliferation under ER stress. 
GSK2606414 triggers biphasic response in the number of viable MiaPaCa-2 cells in 
culture.  The cells were treated with increasing concentrations of GSK2606414 in the 
presence (red) or absence of 0.15 µg/ml tunicamycin (blue) for 72 hours, and the fraction 






Figure 4.18. GSK2606414 induces biphasic response in colony formation of MiaPaCa-
2 cells. 
MiaPaCa-2 cells were treated with various concentrations of GSK2606414 in complete 
medium for 1 hour, followed by addition of 5 µg/mL tunicamycin for an additional 6 hours 
to induce ER stress.  Treated cells were harvested using trypsinization, and replated (500 
cells/ dish) and cultured at 37 °C with 5% CO2 for 10 days.  Images of the colonies formed 





Figure 4.19. Cellular effect of GSK2606414 on PERK signaling. 
MiaPaCa-2 cells were pre-treated with different concentrations of GSK2606414 (1-50 µM) 
followed by UPR induction for 5 hours (5 µg/ml tunicamycin).  Cell lysates were analyzed 
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IC50 for eIF2α  
phosphorylation (µM) 
IC50 for PERK 
autophosphorylation (µM) 
Compound 1 0.068±0.005 0.074±0.009 
Compound 2 0.3±0.002 0.142±0.014 
Compound 3 0.019±0.004 1.186±0.6 
Compound 4 0.045±0.01 0.398±0.11 
 
Table 4.3. Summary of PERK inhibition. 
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Figure 4.S1. Cellular effect of compound 3 on the phosphorylation of PERK in 
HEK293T cells. 
HEK293T cells were pre-treated with different concentrations of compounds (1-50 µM) 
followed by UPR induction for 1 hour (1µM thapsigargin).  Cell lysates were probed for 
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